UTAH MEDICAID DUR REPORT JUNE 2017 BENZODIAZEPINES · 2019. 10. 30. · prescriptions were issued...

UTAHMEDICAIDDURREPORTJUNE2017

BENZODIAZEPINES

AlprazolamChlordiazepoxide

ClobazamClonazepamClorazepateDiazepamEstazolamFlurazepamLorazepamMidazolamOxazepamQuazepamTemazepamTriazolam

DrugRegimenReviewCenter

JoanitaLakeB.Pharm,MScEBHC(Oxon),ClinicalPharmacistElenaMartinezAlonso,B.Pharm.,MScMTSI,MedicalWriterValerieGonzales,Pharm.D.,ClinicalPharmacistVickiFrydrych,B.Pharm.,Pharm.D.,ClinicalPharmacistJoanneLaFleur,PharmD,MSPH,AssociateProfessor

AcknowledgementGaryOderda,PharmD,MPH,EmeritusProfessorMelissaArcher,PharmD,ClinicalPharmacistCarinSteinvoort,PharmD,ClinicalPharmacist

UniversityofUtahCollegeofPharmacyCopyright©2017byUniversityofUtahCollegeofPharmacySaltLakeCity,Utah.Allrightsreserved

2

Contents Introduction .................................................................................................................................................. 4

Background ................................................................................................................................................... 5

Methodology ................................................................................................................................................. 8

Benzodiazepine Products & Indications ....................................................................................................... 8

Pharmacology ............................................................................................................................................... 8

Table 1. Duration of action ....................................................................................................................... 9

Safety .......................................................................................................................................................... 10

Risk factors that increase risk of adverse events ................................................................................... 11

Clinical Guidelines ....................................................................................................................................... 13

Table 2. Clinical Guidelines for the Treatment of Anxiety Disorders ..................................................... 14

Table 3. Guidelines for the treatment of insomnia ................................................................................ 15

Table 4. Other Guidelines/Regulatory Safety updates ........................................................................... 16

Technology assessments/evidence‐based synopses .................................................................................. 18

Table 5. Technology Assessments/Evidence‐based synopses ................................................................ 18

Efficacy ........................................................................................................................................................ 20

Long‐term use ............................................................................................................................................. 21

Comparison of Xanax IR (alprazolam) to Xanax XR and other commonly used anxiolytics ....................... 24

Place in therapy and potential criteria to be reviewed/What can be done to reduce the risk? ................ 26

Utah Medicaid Utilization Data ................................................................................................................... 31

Conclusions ................................................................................................................................................. 38

Appendix 1 – Drug information .................................................................................................................. 39

Table 6. Comparison of Benzodiazepine Agents .................................................................................... 39

Table 7. Warnings and Precautions for the Benzodiazepine Agents ...................................................... 41

Table 8. Pharmacokinetics Properties of the Benzodiazepine Agents ................................................... 42

Appendix 2 ‐ Additional data ...................................................................................................................... 45

Table 11. All claims ................................................................................................................................. 45

Table 12. FFS claims ................................................................................................................................ 46

Table 13. Pediatric claims ....................................................................................................................... 47

Table 14. Number of pediatric patients by age and diagnosis codes ..................................................... 49

Appendix 3 – Exceeding proposed limits and duration of use ................................................................... 50

Table 15. Exceeding proposed limits and duration of use ..................................................................... 50

Table 16. Diagnosis codes submitted ..................................................................................................... 53

Table 17. Diagnosis codes submitted for those exceeding proposed/recommended duration of use . 55

3

Table 18. Diagnosis codes submitted for those exceeding proposed dose limits .................................. 56

Table 19. Top prescribers and number of their claims and patients exceeding the proposed dose limits and duration of use ............................................................................................... 58

References .................................................................................................................................................. 60

4

Introduction The number of people receiving benzodiazepines, benzodiazepine prescriptions, doses prescribed, and overdose mortality have increased considerably.1,3 Benzodiazepine overprescribing, misuse, and abuse contribute to the alarming number of opioid overdoses in the United States. According to the national Treatment Episode Data Set (TEDS) report, between 2000 and 2010, substance abuse treatment admissions reporting both benzodiazepine and narcotic pain reliever abuse increased by more than 500% (5,032 admissions in 2000 to 33,701 admissions in 2010).4 Fourteen benzodiazepine agents are currently available for use in the United States: alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam and triazolam. Benzodiazepines (BZDs) are gamma‐aminobutyric acid (GABA) receptor agonists and have anxiolytic, hypnotic, muscle relaxant, and anticonvulsant properties. Benzodiazepines are widely used to treat anxiety and insomnia. Other therapeutic uses of benzodiazepines include treatment of seizure disorders, alcohol withdrawal symptoms and conscious sedation or general anesthesia. In 2009, approximately 150 million prescriptions were issued in the United States for benzodiazepines–alprazolam (Xanax), clonazepam (Klonopin), and lorazepam were some of the most prescribed psychotropics. Benzodiazepine use has continued to increase.5‐7

20095 20117 #1 alprazolam: 44.5 million prescriptions 49.0 million #6 clonazepam: 23.1 million prescriptions 26.9 million #7: lorazepam: 22.4 million prescriptions 27.6 million #12 diazepam: 14.0 million prescriptions 15 million #17 temazepam: 9.0 million prescriptions 8.5 million

The Drug Enforcement Administration (DEA) also reports that these are the most frequently encountered benzodiazepines on the illicit market. Alprazolam is one of the top three diverted prescription drugs.7 Benzodiazepines are schedule IV controlled substances.7 In 2013, benzodiazepines were involved with approximately 31% of the estimated 22,767 fatal drug overdoses in the United States.3 Widespread and long‐term use of benzodiazepines is occurring despite recommended cautions and concerns (especially in the elderly). Very little evidence supports this practice and other agents remain first‐line recommended therapies (i.e. antidepressants for anxiety disorders).6,8,9 Olfson et al. conducted a retrospective descriptive analysis of benzodiazepine prescriptions to describe benzodiazepine prescription patterns in the United States focusing on patient age and duration of use.10 They used the 2008 LifeLink LRx Longitudinal Prescription database (IMS Health Inc), which included approximately 60% of all retail pharmacies in the United States (adjusting denominators to generalize estimates to the US population), and found that roughly one‐quarter of individuals in all age groups receiving benzodiazepines received long‐acting benzodiazepines, and that long‐term benzodiazepine use is common in the elderly.10 More vigorous clinical interventions supporting judicious benzodiazepine use may be needed to reduce the inappropriate use of benzodiazepines, rates of long‐term benzodiazepine use (especially in older adults), and improve safety outcomes. 1,3,10

5

The main focus of this review is on safety and appropriate use, including: a) Interactions with opioids/CDC recommendations to avoid concurrent use unless alternative

treatment options are inadequate b) Abuse liability: To reduce inappropriate prescribing (e.g., excessive doses or quantities)

Based on expert opinion (Susan L. Siegfreid, MD; Physician, Department of Health), few patients require immediate release (IR) Xanax instead of other products (e.g. use of 4‐5 tabs per month only). Is there any data available comparing Xanax IR (alprazolam) to Xanax extended release (XR) and other commonly used anxiolytics?

c) Long‐term benefit versus risk: To assess whether long‐term use is appropriate d) To help identify and manage patients on long‐term benzodiazepines e) To assess drug‐drug interactions, including both pharmacokinetic and pharmacodynamic issues f) To ensure appropriate use (FDA‐labelled indications) based on the available evidence

The goals of this review are to: 1) Consider quantity limits; 2) Consider restricting concurrent use with opiates except by physician justification; and 3) Consider whether criteria are necessary to ensure appropriate use (per FDA indications) This report will only focus on the benzodiazepines and does not include the non‐benzodiazepine agents (e.g. zolpidem and zaleplon, which are also benzodiazepine receptor agonists). Information from the University of Utah College of Pharmacy Drug Class Reviews for the P&T Committee, Benzodiazepines in the Treatment of Anxiety Disorder November 2016 AND Sedative Hypnotic Benzodiazepines in the Treatment of Sleep Disorders May 2012, have been included.

Background A number of pharmacologic agents belong to the drug class referred to as sedative‐hypnotic agents. Sedative‐hypnotic agents work to induce a calming or sedating effect by depressing the central nervous system (CNS).11 Sedative‐hypnotic agents available in the United States include benzodiazepines, barbiturates and some newer anti‐insomnia agents with unique chemical structures. This review focuses on benzodiazepines. Benzodiazepines have been used therapeutically since the early 1950s and were initially a part of a class of therapeutic agents referred to as tranquilizers.12 The “new” benzodiazepine agents were safer than the older barbiturate agents with far less addiction potential. Presently, benzodiazepines are referred to as sedative‐hypnotic agents and have a number of different therapeutic uses including treatment of anxiety disorders, insomnia, seizure disorders, alcohol withdrawal symptoms and conscious sedation or general anesthesia.11‐13 Darker et al., in a recent Cochrane systematic review, report that “While they [BZDs] can initially be helpful in relieving the symptoms of these problems, many people develop a tolerance to their effects, gain little therapeutic benefit from chronic consumption, become dependent on them and suffer a withdrawal syndrome when they stop taking them.”14 The most common indication for benzodiazepines is anxiety.1,3 According to a recently published study in which the investigators examined data from the Medical Expenditure Panel Survey and multiple‐cause‐of‐death data from the Centers for Disease Control and Prevention, “In 2013, the most common indications for benzodiazepine prescription were anxiety disorders (56.1% [95% CI = 52.2%, 60.1%]),

6

mood disorders (12.1% [95% CI = 9.0%, 15.2%]), and codes in the unclassified category, which includes codes for insomnia (12.0% [95% CI = 9.4%, 14.6%]).”3 Disease Overview: Anxiety The DSM (Diagnostic and Statistical Manual of Mental Disorders) classification is the 5‐axis diagnostic system developed and published by the American Psychiatric Association (APA). The DSM multi‐axial system provides a comprehensive and systematic evaluation of the patient to identify and diagnose mental health disorders.15,16 The axis I DSM psychiatric disorders include the depressive and anxiety disorders. Numerous anxiety disorders are included in this category including: acute stress disorder, agoraphobia, generalized anxiety disorder (GAD), obsessive‐compulsive disorder (OCD), panic disorder and posttraumatic stress disorder (PTSD).15,16 The anxiety disorders are the most common outpatient psychiatric illnesses and up to 75% of patients who have experienced a panic attack will meet the diagnosis for a major depressive disorder. Alcohol and/or substance abuse problems may also occur in patients with anxiety disorders, as a form of self‐medication.17‐22 The medical management of the anxiety disorders includes both pharmacotherapy and psychotherapy. With regard to psychological therapies, cognitive‐behavioral therapy (CBT) is considered the gold standard.23,24 A number of pharmacotherapy options exist for treatment of the anxiety disorders including: tricyclic antidepressants, monoamine oxidase inhibitors, second‐generation antidepressants, anticonvulsants, antipsychotic medications, buspirone and benzodiazepines. Historically, the benzodiazepines were the core of the medical management of anxiety disorders due to their tolerability and rapid onset of action.24 Current guidelines recommend other treatment options first before considering benzodiazepines. Current guideline information is summarized in the guideline section. A short course of a benzodiazepine, at the lowest dose and only on an as‐needed basis, is the usual recommendation for benzodiazepine therapy in the treatment of anxiety disorders. Buspirone, an anxiolytic that may be effective in the treatment of generalized anxiety disorders, is dosed multiple times a day and requires several weeks of therapy before a response is seen.17 The second‐generation antidepressants, including escitalopram, paroxetine, venlafaxine and duloxetine, are labeled for use in GAD and may be safer options for the long‐term treatment of chronic anxiety. Other agents used in the treatment of anxiety include the GABA‐nergic acting anticonvulsants, divalproex, gabapentin, oxcarbazepine, pregabalin and tiagabine.17 Overall, choice of therapy is based on presenting anxiety disorder, patient history and medical costs. The combination of both pharmacotherapy and psychotherapy is beneficial in the treatment of all anxiety disorders.23,24 Disease Overview: Insomnia Insomnia is a disorder defined by difficulty with sleep initiation, duration, consolidation, or quality.25,26 Diagnostic criteria for chronic insomnia specify that “symptoms must cause clinically functional distress or impairment; be present for at least 3 nights per week for at least 3 months; and not be linked to other sleep, medical, or mental disorders.”27 General insomnia disorder occurs despite adequate opportunity for sleep, results in daytime impairment, and causes distress.25,26 Insomnia symptoms occur in up to half of the adult population in the United States.26 Risk factors for insomnia include increasing age, female sex, comorbid disorders, and shift work.25,26 There is also a difference reported between the type of insomnia experienced by younger and older people (difficulty falling asleep vs. waking up after sleep onset).28 Older adults are more likely to experience the latter.28

7

The medical management of insomnia includes both behavioral therapies, pharmacotherapy, or a combination of both.28 Behavioral therapies include: relaxation therapy, stimulus control therapy, and sleep restriction therapy.26 Cognitive Behavioral Therapy (CBT‐I) incorporates sleep restriction, stimulus control, sleep hygiene, and cognitive therapy such as relaxation techniques.29 The American College of Physicians (ACP) Guidelines recommend cognitive behavioral therapy for insomnia (CBT‐I) as the initial treatment for chronic insomnia disorder and that clinicians use a shared decision‐making approach regarding pharmacological therapy (if behavioral therapy fails).28 A number of pharmacotherapy options exist for the treatment of insomnia including: benzodiazepines (triazolam, estazolam, temazepam, flurazepam, and quazepam); benzodiazepine receptor agonists/nonbenzodiazepine hypnotics (zaleplon, zolpidem, and eszopiclone); melatonin receptor agonist (ramelteon); the orexin receptor antagonist (suvorexant); the antidepressant doxepin; and off‐label use of other drugs such as other sedating antidepressants, anticonvulsants, antipsychotic medications, melatonin, or other over‐the‐counter antihistamine and herbal drugs.26,28 According to Lexicomp information, “While experience to date in the management of insomnia principally has been with estazolam, flurazepam, quazepam, temazepam, and triazolam, other benzodiazepines also can be used for insomnia.”30 Before the introduction of the newer benzodiazepine receptor agonist insomnia medications (zolpidem, eszopiclone, zaleplon), drug therapy in the treatment of insomnia was dominated by benzodiazepine agents due to their tolerability and rapid onset of action.26,31 However, the newer agents may now be preferred because of relatively rapid onset of effect, short duration of action, a lower risk of abuse, tolerance, and dependence than the benzodiazepines.30,31 Pharmacotherapy should be considered second line treatment and should be used in conjunction with nonpharmacologic therapy. The pharmacological options were summarized in a recent continuing education by Bethany DiPaula (University of Maryland) as 1st: short‐intermediate acting BZD or benzodiazepine receptor agonist or ramelteon; 2nd: alternate of these as second; 3rd: sedating antidepressants (if concurrent depression/anxiety).29 Suvorexant is a new therapy without sufficient data so it is not currently recommended.29 This was based on the older 2008 guidelines. Guideline information is summarized in the guideline section.28 The recent ACP guidelines are for the management of chronic insomnia and the authors stated that evidence was insufficient to determine the benefits of pharmacologic therapy with benzodiazepines in the general population or in older adults, and that only a few trials met the inclusion criteria because many assessed short durations of treatment.28 Clinical Efficacy information from P&T reports A brief summary of the University of Utah College of Pharmacy Drug Class Reviews for the P&T Committee (Benzodiazepines in the Treatment of Anxiety Disorder November 2016 and Sedative Hypnotic Benzodiazepines in the Treatment of Sleep Disorders May 2012) has been included below. How do the benzodiazepines compare with each other for reducing anxiety symptoms?

In summary, the overall improvements in anxiety outcome measures between alprazolam, clorazepate, diazepam, lorazepam and oxazepam in current literature are similar. The majority of available evidence is captured in nine clinical trials comparing alprazolam to other benzodiazepines. Although some psychometric assessments were more improved for diazepam when compared to alprazolam and clorazepate, total scores for the outcome measures exhibited no differences between treatment groups. Overall, outcome measures were similar between each of the benzodiazepines evaluated in the treatment of anxiety disorders.32‐42

8

How do the benzodiazepines compare with each other for reducing insomnia symptoms? In summary, the majority of the data available comparing diazepam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, and triazolam suggest no major differences in efficacy between the agents in treating insomnia. According to clinical evidence comparing flurazepam to triazolam, flurazepam may be less effective in treating insomnia. Evidence also suggests quazepam is more effective than triazolam and midazolam may be more effective in improving sleep latency. With regard to safety from clinical trials, triazolam may be associated with an increased risk of withdrawal and rebound effects and lorazepam may be associated with an increased adverse event rate. Overall, the clinical data suggest patients should be treated with the lowest effective dose of a benzodiazepine for the shortest possible time in the treatment of insomnia to avoid adverse events.43‐68

Methodology Relevant information from the University of Utah College of Pharmacy Drug Class Reviews (Benzodiazepines in the Treatment of Anxiety Disorder November 2016 AND Sedative Hypnotic Benzodiazepines in the Treatment of Sleep Disorders May 2012) was incorporated into this report. Cochrane Library literature searches for systematic reviews were conducted. Medline (PubMed), Up to Date, the Agency for Healthcare Research and Quality (AHRQ), the U.S. Department of Health and Human Services website, the FDA website (including product labeling information), the Substance Abuse and Mental Health Services Administration (SAMHSA) website,69 University of Maryland Center for Substance Abuse Research (CESAR) website,70 Micromedex, Lexicomp, and the Trip database were searched for safety information, systematic reviews, clinical trials, and other guidelines. References of relevant search results were screened.

BenzodiazepineProducts&Indications Table 6 (Appendix 1) compares all of the benzodiazepine agents in terms of available doses, usual dosage ranges and maximum daily doses, route of administration, labeled and unlabeled uses, metabolites, and whether generics are available.

Pharmacology All benzodiazepine agents enhance the binding of gamma‐aminobutyric acid (GABA), the major inhibitory neurotransmitter, to the GABA‐A subtype of GABA receptors, resulting in GABAnergic neurotransmission.71,72 All benzodiazepine agents exert similar clinical effects. However, differences in their pharmacokinetic profiles, such as rate of absorption, elimination half‐life and lipid solubility, contribute to varying patterns of therapeutic application by influencing onset and duration of action.71,72 Table 8 (Appendix 1) provides a summary of the pharmacokinetic properties for each of the benzodiazepine agents.

9

Table 1. Duration of action73,74 Short‐acting Intermediate‐ acting Long‐acting

Midazolam Alprazolam Clorazepate Triazolam Estazolam Clonazepam Lorazepam Diazepam Oxazepam Flurazepam Temazepam Quazepam Chlordiazepoxide (alone or in combination

with amitriptyline or clidinium)

Short half‐life benzodiazepines (e.g. triazolam) “may be more likely to result in transient rebound insomnia after discontinuance and in pharmacodynamic tolerance and adaptation to the hypnotic effect after several weeks of therapy, with resultant diminished effectiveness during the end of each night’s use (early morning insomnia) and, possibly, increased daytime anxiety.”30

Long half‐life (e.g. flurazepam, quazepam) “may be more likely to result in residual daytime sedative effects and in impaired psychomotor and mental performance during continued therapy, although partial tolerance to these effects can occur.”30

Benzodiazepines with slow GI absorption (e.g., temazepam) “may be less effective in initial sleep induction” so may not be the best option for patients with difficulty in falling asleep (sleep‐latency insomnia), or might have to take it longer before bedtime (e.g. 1‐2 hours before bedtime) to compensate for the delayed onset.30

All benzodiazepine agents result in dependence or tolerance with long‐term use.75,76

ANXIOLYTICS Lorazepam, oxazepam and alprazolam have low hepatic metabolism and do not have active

metabolites Diazepam and chlorazepate are rapidly absorbed benzodiazepine agents and have the most

rapid onset of action but also the greatest abuse/dependence potential. Chlordiazepoxide, clonazepam, clorazepate and diazepam are considered long‐acting

benzodiazepine agents and are associated with accumulation which may result in sedation, cognitive impairment and psychomotor retardation.

Alprazolam and lorazepam are considered short‐acting benzodiazepine agents and have been associated with increased anxiety, insomnia and rebound effects upon discontinuation.17,19,21,22,77,78

SEDATIVE/HYPNOTICS Benzodiazepines are not recommended for use in the elderly according to the American Geriatrics

Society (AGS) Beers Criteria for potentially inappropriate medication use in older adults, but some are prescribed.29,73 Flurazepam and quazepam in particular have long half‐lives and are not recommended in the elderly by insomnia guidelines.29

Safety Adverse reactions The most common drug‐related adverse reactions to benzodiazepines include blurred vision, confusion, drowsiness, dizziness, decreased alertness or concentration, euphoria, lack of coordination, nausea, nightmares and decreased libido. Additionally, hypotension and suppressed breathing have been reported with intravenous use.79,80 Evidence on differences in adverse event rates between benzodiazepine agents is limited. Benzodiazepines differ in their pharmacokinetic profiles which can contribute to differences in adverse event rates.79,80 For example, long‐acting benzodiazepines can accumulate and lead to an increased risk of dizziness, confusion, hypotension, or cognitive impairment. According to the recently published (July 2016) American College of Physicians Guidelines on the management of chronic insomnia disorder in adults and the AHRQ review (which it is based on), observational studies suggest an association of hypnotics with infrequent but serious harms such as dementia, fractures, and major injury.28,81 Table 7 (Appendix 1) provides a summary of the warnings and precautions associated with benzodiazepine therapy. Psychomotor impairment Benzodiazepine agents may cause psychomotor impairment and may increase risk for:

Falls and hip fracture or other injuries, especially in the elderly.82,83 “Benzodiazepines increase the risk of hip fracture in older persons by at least 50%.”6,84 Benzodiazepine drug use is associated with increased risk for falls in older persons.85 Approximately 30% of community‐dwelling and 50% of nursing home adults older than 65 years of age fall every year.85‐87 Leipzig et al85, conducted a systematic analysis of trials evaluating sedative/hypnotic, antidepressant, or neuroleptic drug use with falling in adults aged >60. A total of 40 trials were included in the analysis. Benzodiazepines were found to be associated with increased risk for falls but no statistically significant differences were reported between specific benzodiazepine agents or between the short‐ and long‐acting benzodiazepine agents. Overall, the data suggest all benzodiazepines should be used with caution in geriatric patients.85‐87

Impairment of driving skills; driving under benzodiazepine influence is reported to be about the same risk of driving with a blood alcohol level between 0.050 and 0.079%. Motor vehicle accidents are therefore of particular concern.88,89

Cognitive impairment Long‐term use of BZDs have been associated with:

Dementia14,90

Impaired cognitive attention14,91

Impaired verbal memory14,92 Potential cancer risk “Temazepam is associated with an increase in incident cancer cases.”28

11

Drug‐interactions: Most are substrates for CYP3A4 so could interact with any medications that are inhibitors or inducers (particularly an issue with inhibitors due to increased risk of toxicity).29 Misuse or abuse of benzodiazepines Misuse/abuse/inappropriate use is a problem with benzodiazepines and can be due to prescription sharing or intentional abuse through doctor shopping, fraudulent prescriptions, or drugs obtained through drug dealers (which could be prescription drugs that became street drugs).6,7,14 “According to the National Epidemiologic Survey on Alcohol and Related Conditions, which included 35,000 participants, benzodiazepine prescriptions were associated with nonmedical use (odds ratio = 1.9) and development of benzodiazepine abuse or dependence (odds ratio = 2.6).”6,93 Withdrawal Withdrawal symptoms may be precipitated with benzodiazepine discontinuation, and can occur after only one month of daily use, or according to the authors of a recent systematic review, “at any time up to three weeks after cessation of a long‐acting BZD, or a few hours after cessation of a short‐acting one”.6,14,94 Withdrawal symptoms include anxiety, insomnia, and may also include tinnitus, involuntary movements, nausea, perceptual changes, confusion and seizures.14 Long‐term use can result in a “protracted, uncomfortable withdrawal syndrome that can last for months.”6 Short‐acting benzodiazepines like alprazolam and lorazepam are associated with significant fluctuations between peak and trough levels between doses because these drugs are eliminated fairly rapidly. People often experience more intense withdrawal symptoms and may experience rebound anxiety between doses.95 When discontinuing treatment with these short‐acting benzodiazepines, patients are often switched to long‐acting benzodiazepines such as diazepam which can be reduced by 1 mg every 1‐4 weeks or more and low doses can therefore be achieved (which is difficult with other benzodiazepines).95

Riskfactorsthatincreaseriskofadverseevents Patients with a history of substance abuse: “Those with a history of a substance use disorder are

at higher risk of misusing substances in their futures.”1

High doses: High doses result in more CNS depression. Table 6 (Appendix 1) contains information on the Adult Oral Dosage Range & Maximum Oral doses (adults) for the different benzodiazepines. Investigators of a recently presented study conducted at Mount Sinai Beth Israel in New York City (American Academy of Addiction Psychiatry (AAAP) 27th Annual meeting) involving 241 patients from a psychiatric outpatient clinic that were prescribed benzodiazepines by 18 different clinicians, found that "The average daily benzodiazepine dose was equivalent to about 2.8 mg/day of Ativan (lorazepam, Valeant), but 11% of the patients were getting what the literature has deemed a high dose, which is 6 mg/day of Ativan or more."1 More information on this study can also be found in the Factors to consider section under “As needed” prescribing. Park et al. studied the association between benzodiazepine prescribing patterns including dose, type, and dosing schedule and the risk of fatal overdose among US veterans receiving opioid

12

analgesics in a case‐cohort study.96 They found that the risk of drug overdose was dose‐dependent. “Risk of death from drug overdose increased as daily benzodiazepine dose increased.”96

Extended treatment periods/ Long‐term use: Refer to Long‐term use section

Opioid and benzodiazepine combination: In 2016, the FDA issued a safety alert warning about “serious risks and death when combining opioid pain or cough medicines with benzodiazepines”, and stated that the prescribing of opioid pain medicines with benzodiazepines or other CNS depressants should be limited only to patients for whom alternative treatment options are inadequate.97 “If these medicines are prescribed together, limit the dosages and duration of each drug to the minimum possible while achieving the desired clinical effect.”97

Elderly79,80,98,99: Active metabolite accumulation may occur more frequently in the elderly because of slowed hepatic and renal metabolic activity and may also result in increased adverse events. These patients are at increased risk of residual and cumulative CNS depressant effects.30 FDA labels advise lower doses for older/debilitated adults.81 Pomara et al. state that lorazepam is widely used in the treatment of anxiety and related conditions in the elderly and “negative effects of acute lorazepam administration on cognitive performance, especially memory, have been reported in both previously untreated elderly and in individuals who have received short term (up to three weeks) treatment with therapeutic doses.”100 The authors also conducted a study evaluating its long‐term effect in this population. Pomara et al. (2015) conducted a double‐blind placebo‐controlled cross‐over study assessing the effect of long‐term (at least three months) daily treatment with lorazepam in cognitively intact elderly individuals (n=37). They found that patients had “significantly poorer recall and slowed psychomotor performance following acute lorazepam administration” and “an absence of significant therapeutic benefits.”100

Children: BZDs should generally avoided (due to long‐term risk of dependence)101

Patients with kidney or liver failure (impaired elimination of drugs). It is important to consider appropriateness of a particular benzodiazepine and dosage adjustments in these patients. Diazepam and other long‐acting benzodiazepines may accumulate to toxic levels and may not be appropriate in these patients (e.g. when considering switching to diazepam when discontinuing a short‐acting benzodiazepine).95 Patients with liver disease: decrease dosage (except possibly lorazepam and oxazepam) “Liver and kidney function tests and blood cell counts should be performed regularly during

long‐term therapy, and benzodiazepines should be administered with caution to patients with hepatic or renal disease.”30 (“A few cases of hematological adverse effects have been reported with benzodiazepine use i.e. “leukopenia (including neutropenia and granulocytopenia), agranulocytosis, aplastic anemia, hemolytic anemia, decreased hematocrit, eosinophilia, and leukocytosis.”30)

Patients whose job or lifestyle requires unimpaired intellectual or psychomotor function (increased risk with residual and cumulative CNS depressant effects)30

All parties involved in the treatment process underestimating the degree of impairment caused by benzodiazepines

13

Patients with certain disease states may be at increased risk/polydrug use e.g. patients using more than one sedative‐type drug such as opioids or alcohol.6,79,80,98,99

Patients may have complex psychiatric conditions and “Misuse of BZDs is most often found within a polydrug use pattern (the use of two or more psychoactive drugs in combination to achieve a particular effect) as an attempt to achieve a subjective euphoria or reduce anxiety symptoms or treat the side or withdrawal effects of other drugs of abuse.”14,102 People dependent on opioids may take benzodiazepines to augment the effects of the opiates which increase the risk for synergistic central nervous system and respiratory depression. Opiate dependence is also associated with other risk factors such as HIV and hepatitis C.14 Patients with bipolar disorder According to a psychiatrist from at Mayo Clinic (William V Bobo, M.D.), there is a high prevalence of alcohol and substance use disorder in patients with bipolar disorder.103 In acute settings benzodiazepines may be appropriate to use as adjuncts to core mood stabilizers (“for improving sleep and controlling mania and aggressive behavior”), but long‐term use is of particular concern in these patients because of safety issues related to other substance or alcohol abuse and because of the potential for benzodiazepine abuse.103

ClinicalGuidelines Anxiety Current guidelines from the World Federation of Societies of Biological Psychiatry (2012)104 recommend using a second generation antidepressant as first‐line therapy in the treatment of anxiety disorders because they are effective and well‐tolerated. According to the guidelines, benzodiazepines should only be used in treatment‐resistant patients without a history of substance abuse.104 The most current recommendations from the World Council of Anxiety (2003)105‐110 also support the use of second generation antidepressants as first‐line therapy in the treatment of anxiety disorders. According to the World Council of Anxiety, benzodiazepines may be beneficial in the short‐term treatment of anxiety disorders but their adverse‐effect profiles limit use in the long‐term treatment of anxiety disorders.105‐110 In general, short‐term is defined as ≤ 4 months. The APA has published individual practice guidelines with recommendations for each of the individual anxiety disorders.111‐113 Overall, the APA recommends using a second generation antidepressant as first‐line therapy for the treatment of PTSD, OCD or panic disorder. Benzodiazepines are recommended only as add‐on therapy for patients who are treatment‐resistant to first‐line treatment.111‐113 Guidelines from the American Academy of Child and Adolescent Psychiatry recommend treatment with a second‐generation antidepressant if CBT is unsuccessful in the treatment of OCD in pediatric patients (2012).114 Two National Institute for Health and Care Excellence (NICE) guidelines are available: one addressing the management of general anxiety and panic disorders in adults19 and one developed by the National Collaborating Centre for Mental Health on behalf of NICE addressing social anxiety disorder.20 Both guidelines recommend the second‐generation antidepressant agents for first‐line pharmacologic treatment. According to the guidelines, benzodiazepines should only be used short‐term in general anxiety and panic disorders and should not be used in social anxiety disorder. Table 2 summarizes the current clinical practice guidelines available for the treatment of anxiety disorders.

14

Table 2. Clinical Guidelines for the Treatment of Anxiety Disorders

Guideline Recommendations

Guidelines for the pharmacological treatment of anxiety disorders, obsessive‐compulsive disorder and posttraumatic stress disorder in primary care; World Federation of Societies of Biological Psychiatry (2012)104

First‐line pharmacological treatments

selective serotonin reuptake inhibitors for all anxiety disorders

serotonin‐norepinephrine reuptake inhibitors in GAD, panic disorder, agoraphobia

pregabalin for generalized anxiety disorder only Combination of medication and cognitive behavior therapy is the clinically desired treatment strategy. Benzodiazepines should be used as needed and short‐term, in addition to a regular pharmacological treatment regimen. Of note, benzodiazepines were not found to be effective in acute stress disorder and in conditions with depression comorbidity or OCD.

Practice parameter for the assessment and treatment of children and adolescents with obsessive‐compulsive disorder; American Academy of Child and Adolescent Psychiatry (2012)114

When possible, CBT is the first line treatment for mild to moderate cases of OCD in children. For moderate to severe OCD, medication is indicated in addition to CBT. Serotonin reuptake inhibitors (SRIs) are the first‐line medications recommended for OCD in children and should be monitored closely for response, tolerability and safety.

NICE: Generalized anxiety disorder and panic disorder in adults: management. [CG113], 201119

First‐line:

Choice of high‐intensity psychological intervention (cognitive behavior therapy (CBT) or applied relaxation or drug treatment

Psychological Intervention: 12 to 15 1‐hour sessions of psychological intervention

Pharmacological Treatment: Selective serotonin reuptake inhibitor (SSRI) Second‐line:

A second SSRI or serotonin/norepinephrine reuptake inhibitor (SNRI)

If unable to tolerate SSRI/SNRI, consider pregabalin

ONLY use benzodiazepine short‐term

Do NOT use antipsychotics for GAD

NICE: Social anxiety disorder: recognition, assessment and treatment NICE guidelines [CG159], 201320

Interventions:

Cognitive behavioral therapy (CBT). Promote CBT before pharmacological therapy.

For Partial Response to CBT, consider combination of drug therapy and CBT o Pharmacologic therapy: selective serotonin reuptake inhibitor (SSRI) such as

escitalopram or sertraline.

For Partial Response to Drug Therapy (after 12 weeks) or Side Effects: o Alternative SSRI (fluvoxamine or paroxetine) or serotonin/norepinephrine

reuptake inhibitor (SNRI), such as venlafaxine o Monoamine oxidase inhibitor (MAOI) such as phenylzine or moclobemide

NOT recommended: pharmacological interventions including anticonvulsants, tricyclic antidepressants, benzodiazepines, or antipsychotic medication, St. John’s wort or other over‐the‐counter preparations

Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder, APA (2004)111

Treatment of ASD or PTSD symptoms includes three broad categories of intervention: pharmacological treatment, psychotherapeutic intervention and education and supportive measures. SSRIs are recommended as first‐line medication treatment for PTSD. Other antidepressants (Tricyclic antidepressants and MAOIs) and benzodiazepines may also be beneficial as second‐line or add‐on options.

15


Practice guideline for the treatment of patients with obsessive‐compulsive disorder, APA (2007)112

CBT and SSRIs are recommended on the basis of clinical trial results as safe and effective first‐line treatments for OCD; “Clomipramine, fluoxetine, fluvoxamine, paroxetine, and sertraline, which are approved by the FDA for treatment of OCD, are recommended pharmacological agents.” Strategies for Moderate Response: Augment with a second‐generation antipsychotic or with CBT, if not already provided. Strategies for Little or No Response: Switch to a different SSRI (may try more than one trial), switch to clomipramine, augment with a second‐generation antipsychotic, switch to venlafaxine, switch to mirtazapine. Benzodiazepines cannot be recommended as monotherapy for OCD.

Practice guideline for the treatment of patients with panic disorder; APA (1998, update 2009)113

The use of an SSRI, SNRI, TCA, benzodiazepine (appropriate as a monotherapy only in the absence of a co‐occurring mood disorder) or CBT as the initial treatment for panic disorder is strongly supported by demonstrated efficacy in numerous controlled trials.

Key: GAD=generalized anxiety disorder, SSRI=selective serotonin reuptake inhibitor, SNRI=selective serotonin/norepinephrine reuptake inhibitor, CBT=cognitive behavior therapy

Insomnia The recent American College of Physicians (ACP) Guidelines recommends cognitive behavioral therapy for insomnia (CBT‐I) as the initial treatment for chronic insomnia disorder and that clinicians use a shared decision‐making approach with regards to pharmacological therapy (if behavioral therapy fails).28 Pharmacologic treatment should be considered second line treatment and should be used in conjunction with nonpharmacologic therapy. The authors stated that evidence was insufficient to determine the benefits of chronic benzodiazepine therapy in the general population or in older adults, and that only a few trials met the inclusion criteria because many assessed only short durations of treatment.28

Table 3. Guidelines for the treatment of insomnia


Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians (2016)28

1. Initial treatment for chronic insomnia treatment: Cognitive behavioral therapy for all adult patients (Grade: strong recommendation, moderate‐quality evidence)

“Cognitive behavioral therapy for insomnia consists of a combination of treatments that include cognitive therapy around sleep, behavioral interventions (such as sleep restriction and stimulus control), and education (such as sleep hygiene). It can be performed in primary care. There are various delivery methods for CBT‐I, such as individual or group therapy, telephone‐ or Web‐based modules, or self‐help books. Most studies focused on in‐person CBT‐I; however, the data suggest that other delivery methods are also effective.” 2. Clinicians should use a shared decision‐making approach (“including a discussion of

the benefits, harms, and costs of short‐term use of medications, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom cognitive behavioral therapy for insomnia (CBT‐I) alone was unsuccessful.”) (Grade: weak recommendation, low‐quality evidence)

Pharmacotherapy: The guidance state that evidence was insufficient for pharmacologic therapy or the choice of agent to treat patients if CBT‐I alone was unsuccessful. In the benefits/harms consideration, the American College of Physicians Guidelines state that evidence was insufficient to determine the benefits of pharmacologic therapy with benzodiazepines in the general population or in older adults, and that only a few trials met the inclusion criteria because many assessed short durations of treatment.

16


Clinical Considerations:

Medications not longer than 4 to 5 weeks (ideally). They state that the skills learned in CBT‐I can manage insomnia over the longer term.

It is recommended that clinicians consider treatable secondary causes of insomnia (e.g. restless leg syndrome, depression, pain, benign prostatic hypertrophy, substance use disorder, sleep apnea, etc.) before recommending to continue insomnia medications.

“If after a trial of CBT‐I, a shared decision is made to continue medications for longer than 4 to 5 weeks, clinicians should revisit the need for medication continuation at periodic intervals.”

“Chronic insomnia disorder itself may have deleterious health effects. However, whether medications decrease the harmful health effects of sleep deprivation is unknown, and evidence is insufficient to assess the balance of benefits and hams from long‐term use of medications.”

Older patients: more sensitive to adverse effects of medications and should be monitored closely.

American Academy of Sleep Medicine (2008)26

Recommend using pharmacotherapy in combination with behavioral therapy in the treatment of insomnia. 1. First‐line recommended pharmacotherapy: short to intermediate acting

benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon, and temazepam) or ramelteon.26

2. Lowest effective maintenance dosage, accompanied by patient education, and followed on a regular basis to assess for safety and effectiveness.26

Obvious concerns regarding potential harms were noted in the American College of Physicians Guidelines: “Harms were insufficiently reported in many of the included randomized controlled trials (RCTs), which most often provided data only on study withdrawals. In addition to evidence from the systematic review on study withdrawals and adverse effects, specific adverse effects associated with the various pharmacologic treatments are summarized in Appendix Tables 4 and 5 of the original guideline document. Data from observational studies suggest that serious adverse effects, such as dementia and fractures, may be associated with hypnotic drugs. Product labels from the U.S. Food and Drug Administration (FDA) warn patients about cognitive and behavioral changes, such as possible driving impairment and motor vehicle accidents, as well as other adverse effects. The FDA also recommends lower doses of benzodiazepine and nonbenzodiazepine hypnotics in women and in older or debilitated adults. In addition, the FDA recommends short‐term use of these drugs, although many patients may continue their use for extended periods.”

Table 4. Other Guidelines/Regulatory Safety updates


CDC Guideline for Prescribing Opioids for Chronic Pain ‐ United States, 2016.115,116 Note that this is a main

Avoid concurrent opioids and benzodiazepines whenever possible “Benzodiazepines and opioids both cause central nervous system depression and can decrease respiratory drive. Concurrent use is likely to put patients at greater risk for potentially fatal overdose.”

17


American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults73

Avoid benzodiazepines in older adults “Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long‐acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults.” “May be appropriate for seizure disorders, rapid eye movement sleep disorders, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia.” Quality of evidence: Moderate Strength of recommendation: Strong

2015 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Due to Drug‐Disease or Drug‐Syndrome Interactions That May Exacerbate the Disease or Syndrome73 Only included information regarding benzodazepines. Please refer to the guidelines for complete information.

Delirium

Avoid benzodiazepines “in older adults with or at high risk of delirium because of the potential of inducing or worsening delirium”

Dementia or cognitive impairment

Avoid benzodiazepines “because of adverse CNS effects” History of falls or fractures

May cause ataxia, impaired psychomotor function, syncope, additional falls; shorter‐acting benzodiazepines are not safer than long‐acting ones => Avoid unless safer alternatives are not available

If one of the drugs must be used, consider reducing use of other CNS‐active medications that increase risk of falls and fractures (i.e., anticonvulsants, opioid‐receptor agonists, antipsychotics, antidepressants, benzodiazepine receptor agonists, other sedatives and hypnotics) and implement other strategies to reduce fall risk

American Academy of Sleep Medicine Clinical Practice Guideline: The treatment of restless legs syndrome and periodic limb movement disorder in adults—an update for 2012: practice parameters with an evidence‐based systematic review and meta‐analyses.117

STANDARD level of recommendation (for both medications: high body of evidence; benefit clearly outweighs harm; FDA indication) pramipexole and ropinirole. GUIDELINE level of recommendation: levodopa with dopa decarboxylase inhibitor (high body of evidence; benefits closely balanced with harms; off‐label use) opioids (low body of evidence; benefits clearly outweighs harms; off‐label use) gabapentin enacarbil (high body of evidence; uncertain benefits vs. harms; FDA indication) cabergoline (only use if other recommended agents have been tried first due to side effects including heart valve; high body of evidence; benefits closely balanced with harms; off‐label) OPTION level of recommendation (all low body of evidence or very low for ferritin; all off‐label use) Carbamazepine (benefits closely balanced with harm) Gabapentin (unclear benefit vs harm) Pregabalin (benefits closely balanced with harm Clonidine (unclear benefit vs harm) Iron supplementation if low ferritin levels (unclear benefit vs harm) Refer to guidelines for recommendations secondary to end stage renal disease (ESRD), neuropathy, and superficial venous insufficiency. Benzodiazepines (clonazepam) “There is insufficient information on the effect of benzodiazepines on the treatment of RLS.” (few small studies with contradictory results) “The committee strongly recommends that alternate and better studied RLS medications be considered in RLS therapy. The “no recommendation” status applies to the use of benzodiazepines as a first line agent. For example, clonazepam could still be considered as an adjunctive medication in treatment of RLS.”

18


Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update 6 July 2011 Addiction to benzodiazepines and codeine118

“Reminder for healthcare professionals:

given the risks associated with the use of benzodiazepines, patients should be prescribed the lowest effective dose for the shortest time possible. Maximum duration of treatment should be 4 weeks, including the dose‐tapering phase”

American Board of Internal Medicine Foundation Choosing Wisely Campaign (2012)119,120 Also, as part of this campaign: American Geriatrics Society (2013)119,121

“Recommends against the use of benzodiazepine drugs for adults 65 years and older.” “advised physicians and patients to refrain from using benzodiazepines as first‐line treatment for insomnia in older adults.” Refer to 2015 AGS guidelines above.

NICE Guidance: Depression in adults: recognition and management (CG90) Published date: June 2016122

Do Not Do Recommendation The guidance include three strategies that should not be used routinely of which one involves benzodiazepines:

“augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence”

Technologyassessments/evidence‐basedsynopses

Table 5. Technology Assessments/Evidence‐based synopses

Technology Assessment Findings

Canadian Agency for Drugs and Technologies in Health. Short‐ and long‐term use of benzodiazepines in patients with generalized anxiety disorder: a review of guidelines. 28 July 2014123

KEY FINDINGS “The short‐term use of benzodiazepines for the treatment of generalized anxiety disorder is recommended as adjunctive therapy to antidepressants until their effectiveness is apparent or in times of acute crisis or increased anxiety. One guideline specified a daily dosage of alprazolam ranging between 1.5 mg and 6 mg when used to control the anxiety associated with first‐line use of antidepressants. Long‐term use of benzodiazepines is only recommended in patients who do not respond to or cannot tolerate numerous first‐line therapies. No recommendations were provided on the maximum daily doses for long‐term BZD treatment for GAD. For special populations, the guidelines generally advise against the use of BZDs in the elderly (or to use at lower adult doses if required), to use them sparingly in children and adolescents, and to use them with caution during the first and third trimesters of pregnancy, during labour and delivery, and when breastfeeding.”

Canadian Agency for Drugs and Technologies in Health. Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost‐Effectiveness, and Guidelines January 2011124

Published in 2011 and included guidelines published 2005‐2010 so it would be better to rather refer to the 2015 updated BEERS criteria.73 However, their review included below did not include BEERS criteria either.

19

Technology Assessment Findings

Canadian Agency for Drugs and Technologies in Health. Treatment of Older Adults with Insomnia, Agitation, or Delirium with Benzodiazepines: Clinical Effectiveness and Guidelines. 2016

They did not identify any studies or guidelines on benzodiazepines in older adults based on their selection criteria.

Canadian Agency for Drugs and Technologies in Health. Discontinuation Strategies for Patients with Long‐Term Benzodiazepine Use: Clinical Evidence and Guidelines. 22 January 2015125

“Three systematic reviews and meta‐analyses126‐128, two randomized controlled trials129,130*, and five non‐randomized studies131‐135 were identified regarding strategies to safely and effectively discontinue adult patients from long‐term benzodiazepine use.”

Canadian Agency for Drugs and Technologies in Health. Developmental effects of in utero exposure to prescription drug abuse in infants and young children: harms. 5 November 2014136

“Two systematic reviews and fourteen non‐randomized studies regarding the developmental harms in infants and young children associated with in utero exposure to prescription drug abuse were identified.” The selection criteria included opioids, stimulants, benzodiazepines and gabapentins, but none of the evidence identified was regarding benzodiazepines.

Canadian Agency for Drugs and Technologies in Health. Long‐term Use of Benzodiazepines: Clinical Effectiveness and Safety. 6 July 2015

“Research Questions: 1. What is the clinical effectiveness of long‐term versus short‐term use of benzodiazepines? 2. What is the clinical evidence regarding the safety of long‐term use of benzodiazepines?” Refer to Duration of use section.

*In 2015, Tannenbaum commented in BMJ on what is known about interventions for long‐term benzodiazepine use, what the Vicens et al. (2014)129 study added, limitations, future research, and whether these results would change her practice and why? Her response to the latter was: “Yes. Discussions about benzodiazepine discontinuation with chronic users were previously thought to be excessively time‐consuming and of little value. Knowing that one‐in‐two patients will successfully taper after a 20 min conversation and distribution of a tapering protocol—without the need for close follow‐up—is a strong motivator for introducing this routine into my practice. These results provide a way to personally contribute to the reduction of potentially harmful treatments as advocated by the Choosing Wisely campaign for physicians (http://www.choosingwisely.org/).”137 In 2016, Vicens et al. assessed whether the interventions that were shown to be successful at 1 year to promote cessation of long‐term benzodiazepine use (Vicens et al. 2014129), were also efficacious at 3 years.138 The authors found that they were successful after 3 years (“patients that discontinued at 12 months remained abstinent at 3 years”) and that “discontinuation of BZD use did not have a significant effect on anxiety, depression, or sleep quality.”138

20

Efficacy The American College of Physicians 2016 Guideline for the management of chronic insomnia was based on a systematic review of randomized controlled trials published 2004 through September 2015; a full evidence report,81 and 2 background evidence review papers.139,140 The evidence review was sponsored by the Agency for Healthcare Research and Quality (AHRQ). The full evidence report included “181 unique studies (data from 128 unique RCTs and 3 systematic reviews that synthesize data from 42 unique RCTs) and 12 observational studies,” but most trials were short‐term studies.81 Sufficient evidence was identified for cognitive behavioral therapy for insomnia (CBT‐I) which “improved global outcomes and nearly all sleep parameters in the general adult population, older adults, and adults with pain”.81 Less evidence exist for other psychological interventions.81 “Low‐ to moderate‐strength evidence indicated that the nonbenzodiazepine hypnotics eszopiclone and zolpidem, and the orexin receptor antagonist suvorexant, improved short‐term global and sleep outcomes in general adult populations. Doxepin improved sleep outcomes. The absolute mean effect was small. Evidence for benzodiazepine hypnotics, melatonin agonists, and antidepressants in general populations and for most pharmacologic interventions in older adults was generally insufficient.”81 The full publication contains tables that summarize all the available evidence for the general population and for older adults.81 McCleery et al. (2016 Cochrane review) assessed treatments for sleep disorders in people with dementia and found no RCTs of benzodiazepines (and other drugs) that are widely prescribed for sleep problems in dementia.141 The authors also mention the uncertainties with regard to benefits vs. risks associated with these common treatments in their conclusion.141 Bighelli, I. et al. (2016 Cochrane review) assessed antidepressants and benzodiazepines for panic disorder in adults.142 They only found a few trials, low quality evidence of no difference between antidepressants and benzodiazepines in terms of response rate, and they did not “find clinically significant differences between individual benzodiazepines.”142 However, they report many limitations such as no information provided regarding random sequence generation and allocation concealment and blinding, and “the study protocol was not available for almost all studies so it is difficult to make a judgment on the possibility of outcome reporting bias. Information on adverse effects was very limited.”142 They therefore conclude that there is insufficient evidence. “…the possible role of antidepressants and benzodiazepines should be assessed by the clinician on an individual basis”, and choice should be based on overall evidence of efficacy and tolerability and by considering long‐term tolerability issues.142 Examples of off‐label uses with currently available evidence Disturbed behavior / to reduce psychotic symptoms / schizophrenia Gillies et al. (2013 Cochrane review) assessed the effects of using benzodiazepines to control disturbed behavior and reduce psychotic symptoms either alone or in combination with antipsychotics and concluded that the evidence is not good/insufficient for using them alone or adding them to other drugs, and they have the potential for additional unnecessary adverse effects.143 Dold, et al. (2012 Cochrane review)144 found that “There is currently no convincing evidence to confirm or refute the practise of administering benzodiazepines as monotherapy or in combination with antipsychotics for the pharmacological treatment of schizophrenia and schizophrenia‐like psychosis.

21

Low‐quality evidence suggests that benzodiazepines are effective for very short‐term sedation and could be considered for calming acutely agitated people with schizophrenia.”144 Neuropathic pain and fibromyalgia Corrigan, R. et al. (2012 Cochrane review)145 assessed the efficacy and safety of clonazepam in the treatment of neuropathic pain and fibromyalgia (in adults) and found no evidence to support its use in these indications. Relief of breathlessness Simon, S.T. et al. (2016)146 assessed the use of benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases (in adults) and found no evidence for or against benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD. However, most studies included were small and had an unclear risk of bias so there is a need for well‐conducted and adequately powered studies. The authors supposed that “benzodiazepines may be considered as a second‐ or third‐line treatment, when opioids and non‐pharmacological measures have failed to control breathlessness.”146 As a muscle relaxant in the treatment of rheumatoid arthritis (RA) Richards, B.L. et al. (2012)147 evaluated the efficacy and safety of muscle relaxants (which included benzodiazepines) in the treatment of RA pain. All included trials were rated by the authors at high risk of bias. There were concerns about the associated adverse effects of muscle relaxants (predominantly drowsiness and dizziness), even short‐term, and the authors concluded that “Based upon the currently available evidence in patients with RA, benzodiazepines (diazepam and triazolam) do not appear to be beneficial in improving pain over 24 hours or one week. However, even short term muscle relaxant use (24 hours to 2 weeks) is associated with significant adverse events, predominantly drowsiness and dizziness.”147

Long‐termuse Short‐term treatment was initially recommended based on the duration of trials (e.g. 2‐3 weeks) and since due to insufficient evidence (most trials are of short duration)28 and the potential adverse effects28 and misuse/abuse sequela. However, in clinical practice benzodiazepines are often used for much longer.29 Some have reported that duration of treatment is somewhat controversial,29,148 but guidelines, recommendations by regulatory bodies and product information recommend that benzodiazepine treatment be limited to short‐term use. However, despite repeated recommendations and warnings, prescribers are still prescribing them for months or years.149 Investigators of the study mentioned under ‘Increased risk factors: High doses’ (presented at the American Academy of Addiction Psychiatry (AAAP) 27th Annual meeting), noted that it was interesting to see that “the majority of patients in the sample (60%) had been receiving benzodiazepines for 5 years or longer” even though it is indicated for “short‐term, limited duration of use because there aren’t many illnesses that necessitate long‐term use of benzos.”1 It is not only opioid dependence and abuse that has become a major problem. Benzodiazepine dependence and misuse/abuse is recognized as a major clinical problem and in the UK for example, “the National Performance Assessment Framework for the NHS makes it a national priority to reduce this within each health board area. Junior doctors who have recently graduated from medical school are commonly placed in rotations where they have to manage patients on benzodiazepine prescriptions. It is necessary for doctors in general to be aware of the essentials of benzodiazepines not only for the

22

adequate management of patients on chronic benzodiazepine prescriptions, but also for responsible prescription of this drug when it is appropriate.” Authors of the recently published (July 2016) American College of Physicians Guidelines on the Management of chronic insomnia disorder found that most studies were short‐term. Long‐term adverse effects are unknown with some observational studies indicating rare, but serious harms.28,81 The authors therefore state that “as indicated on FDA labeling, pharmacological treatments for insomnia are intended for short‐term use, and patients should be discouraged from using these drugs for extended periods.”28 The effectiveness of benzodiazepines for long‐term use as anxiolytics (i.e., Lexicomp states > 4 months as anxiolytics and >4‐10 weeks for panic disorder) has not been established either and continued therapy with benzodiazepines should be reassessed periodically.30 Dosages may require frequent adjustments due to the episodic nature of anxiety.30 Even though we are not focusing on epilepsy/seizure disorders, it is worth mentioning that usefulness in the long‐term management of seizure disorders is limited by the fact that tolerance often develops to anticonvulsant effects of benzodiazepines.30 Regulatory authorities (FDA and MHRA) recommend that the duration of use of benzodiazepines be limited to 2 to 4 weeks. There has been concerns about the risk of dependence and withdrawal reactions after long‐term use of benzodiazepines since the 1980s.118 In fact, the MHRA safety alert (July 2011) reminded healthcare professionals that “patients should be prescribed the lowest effective dose for the shortest time possible. Maximum duration of treatment should be 4 weeks, including the dose‐tapering phase.”118 CADTH prepared a report/reference list on the long‐term use of benzodiazepines in terms of clinical effectiveness and safety.150 The report states that they identified two systematic reviews (Billioti et al. (2015)151 and Sim et al. (2015)152, one meta‐analysis (Zhong et al. (2015)148, and three randomized controlled trials.100,153,154 However the latter (of the 3 RCTs) was a preliminary explorative study in which the effects of temazepam was assessed for a week in patients with COPD to determine the feasibility to perform a larger study.154 Billioti et al.151 found that nine out of ten studies reported an increased risk of dementia in benzodiazepine users, and that the “risk increased with cumulative dose and treatment duration and when long‐acting molecules were used.” They therefore conclude that “the body of evidence seems sufficient for avoiding prescriptions or renewals that are not fully justified and indiscriminate long‐term use.”151 Sim et al.152 examined the clinical outcomes for benzodiazepines in schizophrenia. This included two long‐term studies that compared benzodiazepines with first‐generation antipsychotics (FGAs) in which greater global improvements were reported for antipsychotics. The authors concluded that “Benzodiazepine superiority over placebo was found for global, psychiatric and behavioural outcomes, but inferiority to antipsychotics on longer‐term global outcomes. Conflicting evidence exists regarding the addition of benzodiazepines to antipsychotics; thus the use of benzodiazepines in clinical practice and antipsychotic trials should be limited.”152 Zhong et al. included six studies (11,891 dementia cases and 45,391 participants) in their review and found that “long‐term benzodiazepine users have an increased risk of dementia compared with never users” and that the “risk of dementia increased by 22% for every additional 20 defined daily dose per year (RR, 1.22, 95%CI 1.18‐1.25).”148 These investigators included “nested case‐control or prospective

23

cohort studies that provided risk estimates on the association of benzodiazepine use with risk of dementia, and a clear definition of status of benzodiazepine use.”148 The authors state that the findings should be treated with caution until more evidence is available from large prospective cohort studies with long follow‐up duration.148 As is the case with any medication with abuse potential, prescribing excessive quantities of benzodiazepines may lead to misuse and abuse and its associated adverse sequela (not just by the patient, but also other people). It is important to note that dependence does not mean addiction. Patients may need higher doses because of tolerance and strategies to prevent this include considering alternating agents, or not taking the benzodiazepine every night.29 It is recommended to “implement periodic tapers for consecutive administration to determine continued need” and to “consider supplementing with Cognitive Behavioral Therapy (CBT) during taper.”29 Darker et al. in a Cochrane review reported that “long term use of BZDs is not generally recommended and can lead to physical and psychological dependence and withdrawal symptoms when patients reduce or stop using them.” In this Cochrane review, the authors aimed ‘to measure the effectiveness of psychosocial interventions for treating people who harmfully use, abuse or are dependent on benzodiazepines (BZDs).’ Others have also evaluated interventions for benzodiazepine harmful use.137,155 There is conflicting evidence regarding long‐term benzodiazepine use and cognitive decline. Chung, Jun Ku et al. (2016)156 in a small pilot study found that long‐term benzodiazepine use (6 months or longer) was not associated with cognitive decline, but according to Dr Cheong (Professor of psychiatry, University of Florida College of Medicine) "Just because it does not 'prove' that there is a direct link between benzodiazepine use and the development of cognitive decline or dementia, it does not necessarily disprove that there is a link between benzodiazepines and cognitive decline." Dr Maust (University of Michigan) noted that the sample size is small and Alzheimer's Disease Neuroimaging Initiative (ADNI) patients are not at all representative of the general population (average years of education in the benzodiazepine group was more than 16 years). These clinicians stated that benzodiazepines should be used with caution in the elderly because of the link between benzodiazepines and falls, fractions, car accidents, confusion, amnesic effects, and cognitive impairment.157 Gray et al. in a recently published population based cohort (mean follow‐up of 7.3 years) found that “The risk of dementia is slightly higher in people with minimal exposure to benzodiazepines but not with the highest level of exposure. These results do not support a causal association between benzodiazepine use and dementia.”158 As mentioned earlier, in acute settings benzodiazepines may be appropriate to use as adjuncts to core mood stabilizers (“for improving sleep and controlling mania and aggressive behavior”103) in patients with bipolar disorder, but long‐term use is of particular concern in these patients because of safety issues related to other substance or alcohol abuse issues and because of the potential for benzodiazepine misuse or abuse.103 Currently there is limited evidence available and there is a need for additional studies. Based on limited evidence (and trial limitations), it appears that long‐term benzodiazepine use in these patients may not significantly affect outcomes and there is a potential for abuse and an association with recurrences.159 Another study by the same research team using data from the same study explored the characteristics of patients that received benzodiazepines and it appears that these patients had more complex psychiatric symptoms and received more psychotropic medications in an attempt to achieve better control of symptoms.160 Overall, there is insufficient evidence to make specific recommendations or to give a complete understanding of scenarios when long‐term benzodiazepine use would be beneficial or detrimental, but these results provide some

24

insight into factors to consider. A cautious approach assessing the potential improvement (or not) weighed against the potential risks should be considered individually for every patient and should be reviewed regularly.

In general, there is agreement that apart from exceptional circumstances (e.g. terminally ill patients), there is no evidence to support long‐term use of BZDs and major safety concerns exist.74 Some patients report enhanced sleep with long‐term use, but it is reported that the effect wears off in a few weeks and rebound insomnia is experienced upon cessation, thus there is no objective evidence to support long‐term use.6 According to a recent editorial by BRIAN JOHNSON, MD, State University of New York Upstate Medical University, New York, it is unclear where long‐term benzodiazepine use fits into current medical practice. However, he discusses the associated risks and factors that would increase the risks (which has been incorporated into the report).

ComparisonofXanaxIR(alprazolam)toXanaxXRandothercommonlyusedanxiolytics According to the recently published (July 2016) American College of Physicians Guidelines on the Management of chronic insomnia disorder in adults and the AHRQ review, there was insufficient evidence overall on the comparative effectiveness and safety of the various pharmacologic treatments (within or across classes).28,81 Evidence was also insufficient to compare medications with CBT‐I.28,81 Bighelli et al. (2016 Cochrane review) did not find clinically significant differences between benzodiazepines when they assessed benzodiazepines and antidepressants for effects in panic disorder.142 In general, it was noted in the literature that the risk of abuse might be higher with fast‐acting benzodiazepines such as lorazepam and alprazolam (Xanax) compared to clonazepam which is believed to have a lower risk of abuse because of the “slow‐on and slow‐off action.”101 The Drug Enforcement Administration (DEA) also reports that it is particularly the rapid onset benzodiazepines that are abused to produce euphoric effects.7 FDA approved (labeled) indications for alprazolam formulations are as follows: “Anxiety disorders (immediate release tablet, oral concentrate, orally‐disintegrating tablets): Treatment of generalized anxiety disorder (GAD), short‐term anxiety and anxiety association with depression Panic disorder (extended‐release tablets, oral solution, orally‐disintegrating tablets, immediate‐release tablets): Treatment of panic disorder, with or without agoraphobia”30 Comparison of pharmacokinetics of alprazolam IR and XR161 Similarities Differences IR & XR IR XR

Bioavailability Distribution Metabolism Elimination Extent of accumulation

Narrow/short therapeutic window*

Blood drug levels rapidly climb into toxic range (greater side effects), followed by

Rapid descent of blood drug levels below the minimum effective concentration

Wider therapeutic window* resulting in:

Fewer side effects Less breakthrough anxiety before next dose

25

Similarities Differences IR & XR IR XR

“Clock‐watching effect”=> therapeutic effects disappear rapidly (well before time for the next dose)

Duration of action: 4‐6 hours Duration of action: ≥12 hours

*Therapeutic window: below toxicity range and above the minimum effective concentration

No Cochrane or other reviews were identified in the Cochrane Library comparing alprazolam IR to XR, only some clinical trials that are discussed below. In 1995, Klein in a review, based on 3 small studies, reported that benzodiazepines with short half‐lives were associated with a higher risk of discontinuation difficulties compared to those with long half‐lives.162 “The nature of the anxiety disorder for which treatment is prescribed might also have a bearing on successful medication discontinuation.”162 The author concluded that alprazolam XR and IR are equally effective, but that alprazolam XR may offer advantages during drug tapering and withdrawal.162 In 1995, Mumford et al. evaluated “the behavioral, subjective, and reinforcing effects of immediate‐release (IR) alprazolam and extended‐release (XR) alprazolam to assess the effect of release rate on laboratory measures of abuse liability.”163 This was a small study (n=14), but it had some interesting results. The authors found that immediate‐release alprazolam had a higher potential for abuse than extended‐release alprazolam.163 In 2007, Leufkens et al. reported that the delayed absorption of alprazolam XR is expected to produce fewer and less severe side effects than alprazolam IR, and therefore should have less effect on potentially dangerous daily activities, such as driving.164 A small study was conducted to explore the effects of alprazolam XR (1 mg) and alprazolam IR (1 mg) on driving ability and cognitive function. The authors concluded that “The acute impairing effects of alprazolam XR 1 mg on driving and psychomotor functions were generally less, as compared to its immediate‐release equivalent, but still of sufficient magnitude to increase the risk of becoming involved in traffic accidents.”164 Poisoning/overdose considerations Buckley et al. (1995) assessed “the sedative effects in overdose of temazepam and oxazepam compared with other benzodiazepines” through a cohort study of patients admitted with benzodiazepine poisoning “to determine if this explains reported differences in fatal toxicity,” and found that “oxazepam produced less sedation and temazepam more when compared to other benzodiazepines.”165 They concluded that their findings “were in accordance with fatal toxicity indices derived from coroners' data on mortality and rates of prescription” and that “the relative safety of benzodiazepines in overdose should be a consideration when they are prescribed.”165 Isbister et al. (2004) studied consecutive deliberate self‐poisonings by searching the database of poisoning admissions to a regional toxicology service in order to describe alprazolam poisoning and the relative toxicity compared to other benzodiazepines.166 “There were 2063 single benzodiazepine overdose admissions: 131 alprazolam overdoses, 823 diazepam overdoses and 1109 other benzodiazepine overdoses.”166 The authors found that alprazolam was significantly more toxic than other benzodiazepines. When comparing overdoses of alprazolam vs. benzodiazepines, the median length of stay was 1.27 times longer, patients were 2.06 times more likely to be admitted to intensive care unit (ICU), flumazenil was administered to 14% vs. 8% and 16% vs. 11% were ventilated, and 12%

26

vs. 10% had a GCS(Glasgow coma scale) <9 indicating coma.166 They conclude that “the increased prescription of alprazolam to groups with an increased risk of deliberate self poisoning is concerning and needs review.”166 Park et al. (2015) studied the association between benzodiazepine prescribing patterns and the risk of death from drug overdose among US veterans receiving opioid analgesics.96 The authors found that in these patients temazepam was associated with a decreased risk of death from drug overdose compared to clonazepam.96 “Benzodiazepine dosing schedule was not associated with risk of death from drug overdose.”96 There are major differences in potency between benzodiazepines. UK Medicines Information (UKMi) pharmacists have prepared a document regarding equivalent doses of benzodiazepines (for UK NHS healthcare professionals) that states there is broad agreement in the literature about equivalent doses, although clonazepam has a wide variety of reported equivalences so particular care is advised.95 Also, inter‐patient variability and differing half‐lives make it difficult to determine exact equivalents.95

Placeintherapyandpotentialcriteriatobereviewed/Whatcanbedonetoreducetherisk? Factors and limitations to consider:

CDC recommends avoiding concurrent opioid and benzodiazepine use. We have reviewed opioids and implemented criteria/strategies to help reduce the opioid misuse/abuse and adverse sequela (i.e. overdose), but many opioid overdose cases involve benzodiazepine use which is an additional risk factor. It is important to also review benzodiazepine use.

‘Holy Trinity’: According to Horsfall & Sprague, current guidelines do not recognize an additional potential risk factor: skeletal muscle relaxants. Opioids, benzodiazepines, and skeletal muscle relaxants are all respiratory depressants. These agents are reportedly combined ('The Holy Trinity') in misuse to potentiate a 'high'.167

Set realistic expectations for insomnia management: Natural changes in sleep occur with age (less sleep when older) and it is important to set realistic expectations.29 Educate about CBT‐I, because most patients that want drugs do not know or trust CBT‐I.

Encourage use of effective alternatives (i.e. education or prior authorization): Anxiety: CBT and antidepressants are the treatments of choice. Insomnia: CBT‐I; refer to guideline and evidence section for options and quality of evidence.

Evaluate appropriateness for indication: Muscle relaxant: There may be some situations when use may be appropriate e.g. diazepam is

indicated a “an adjunct for the relief of acute, painful musculoskeletal conditions”, but may also be used as “short‐ and long‐term management of skeletal muscle spasticity such as reflex spasm secondary to local pathology (e.g., trauma, inflammation), spasticity caused by upper motor neuron disorders (e.g., cerebral palsy, paraplegia), athetosis, stiff‐man syndrome, strychnine poisoning, and tetanus.”30

27

Other short‐term indications: as part of a protocol for treating alcohol withdrawal, urgent treatment of acute psychosis with agitation or acute mania, single‐dose treatment of phobias (e.g. flying phobia), seizures (and a few neurologic disorders), sedation for office procedures.74

Off‐label use: Table 6 includes off‐label uses. Use in bipolar disorder is discussed below (Special populations: patients with complex psychiatric symptoms). Use in the treatment of restless leg syndrome is covered in table 4 (other guidelines). This is an off‐label use and alternatives should be considered e.g. ropinirole (refer to guideline recommendations).74 Burning mouth syndrome: Additional evidence is needed. Limited data suggests that clonazepam may help to reduce pain, but its dependence and abuse potential needs to be considered.30,168‐170 Tardive dyskinesia: Additional evidence is needed. Limited data suggests that clonazepam may be beneficial for the treatment of tardive dyskinesia.30,171 “Based on the American Academy of Neurology guideline for the treatment of tardive syndromes, clonazepam given for tardive dyskinesia is probably effective in decreasing tardive dyskinesia symptoms in the short‐term (approximately 3 months) and is suggested for the short‐term treatment of tardive dyskinesia.”30,172 Tic disorders: Additional evidence is needed. Limited data suggests that “clonazepam may be beneficial for multifocal tic disorder or Tourette disorder.”30,173

Misuse or abuse/inappropriate use of benzodiazepines; Withdrawal symptoms: This can be reduced by prescribing/using the smallest dose for the shortest duration possible; “generally should not be prescribed continuously for more than a month”6; and by tapering the dose gradually.6,94 Use of longer acting agents also decrease withdrawal.

Long‐term use: Basically, there is general agreement that apart from exceptional circumstances (e.g. terminally ill patients, ongoing on‐hand supply for epilepsy, muscle spasm due to conditions such as cerebral palsy and paraplegia), there is no evidence to support long‐term use and there are major safety concerns.74

Pro re nata (PRN) or “as needed” benzodiazepines:

Results of a study conducted at Mount Sinai Beth Israel in New York City was recently presented at the American Academy of Addiction Psychiatry (AAAP) 27th Annual meeting. Researchers found that patients may actually be taking their medications more often when prescribed “as needed” than what the prescribers’ think they should.1,174 In this study, data was gathered on benzodiazepine prescribing from residents and fellows at their psychiatric outpatient clinic in April and May 2015.1,2 The residents and addiction and geriatric fellows in the clinic entered information into a spreadsheet of “who they were prescribing benzodiazepines for, what other medications they were prescribing, what the doses were, and other aspects of their prescribing practices.”1 The most commonly prescribed benzodiazepine was clonazepam (71% of these patients).1 “Based on 241 patients taking benzodiazepines as prescribed by 18 different clinicians, investigators found that those with a pro re nata recommendation were much more likely to exhibit markers of misuse—including requesting early refills, violating the clinic's prescription drug monitoring program, and engaging in a conflict

“New research suggests that while prescribing benzodiazepines "as needed" may be aimed at deterring patients from taking them unless absolutely necessary, the wording may actually foster misuse.”1,2

28

with their health care provider.”2

Educating all parties involved to reduce risks: Explicitly advise the patient regarding the duration of treatment and that long‐term use is not recommended, and review the risks and side‐effects with the patient (including risk of dependence).74 Discontinuing benzodiazepines has been associated with fewer patient falls and improved cognitive and psychomotor function.174 Several references have been identified regarding strategies to safely and effectively discontinue benzodiazepine use.125 As mentioned by Tannenbaum based on the Vicens et al. (2014)129 study, this may just be a matter of making prescribers aware that even something as simple as “a 20 min conversation and distribution of a tapering protocol—without the need for close follow‐up” will result in one‐in‐two patients successfully tapering, and Vicens et al. (2016) found that “patients that discontinued at 12 months remained abstinent at 3 years”, and that “discontinuation of BZD use did not have a significant effect on anxiety, depression, or sleep quality.”138

Special Populations: Are there patient subgroups based on demographics (e.g., age, racial groups, gender) or comorbidities for which one of the benzodiazepines is more effective or associated with fewer adverse effects? Benzodiazepines were evaluated in two special populations: geriatric patients (refer to BEERS criteria73) and patients with a history of substance abuse. Evidence is limited and inconsistent regarding benzodiazepine use in these populations. It is recommended benzodiazepine use be limited in these populations and used only when necessary.

Patients with a History of Drug/Alcohol Abuse It is generally accepted that a history of alcohol or drug abuse suggests a high potential for benzodiazepine abuse.173 Prescribing benzodiazepines in patients with a substance abuse history is controversial.175 There is limited evidence available comparing the benzodiazepines in patients with a history of drug/alcohol abuse.176,177 In two prospective studies, evidence was inconclusive regarding increased risk for abuse in this population.178,179 One longitudinal study found former alcoholics may reduce benzodiazepine use over time.180 Sokolow et al180, followed a cohort of 1,340 patients with a history of alcohol abuse over 8 months. The authors concluded that patients with a history of alcohol abuse are not at higher risk for benzodiazepine abuse. A second study found no differences in benzodiazepine use between patients with a history of substance abuse and patients without a history of substance abuse.181 Romach et al181, evaluated 123 patients taking a benzodiazepine, of which 40% (n = 49) had a history of prior history of alcohol abuse or dependence. Overall, in these studies, the patterns of benzodiazepine use by patients with a history of substance abuse did not indicate abuse, addiction, or drug dependence for any of the patients. Although there is limited evidence for benzodiazepine use in patients with a history of substance abuse, data suggest benzodiazepines may still be used in this population with a comprehensive treatment plan and careful follow‐up.176,177 It is important to remember that benzodiazepines are not first‐line recommended therapies for anxiety or insomnia. If used to treat anxiety or insomnia,

“because the prescriber is saying to take them only when needed,

and the patient may be thinking, 'I can take them as much as I need.'"1

(lead author Amy Swift, MD.)

29

benzodiazepines should be used at the lowest effective dose and on a short‐term basis (≤ 4 months) only. It is a perplexing situation for prescribers to decide which patients with substance abuse histories may be good candidates for not abusing a prescribed benzodiazepine.175 Prescribers have to determine whether they are in fact dealing with a person who has a comorbid condition or a person trying to get them to think they have a comorbid condition.175 Drug seeking behavior include a history of antisocial behavior and dishonesty, multiple prescribers i.e. doctor shopping, patients reciting list of symptoms like it “comes straight out of DSM‐IV” (vs. a patient suffering from anxiety may not even mention “anxiety”), and requests for dose increases or early refills.175 Given that prescribers have to rely on their “clinical feel”175 on a case by case basis, it remains a better option to consider a trial of non‐abusive treatment options first. If benzodiazepines are prescribed, limiting quantities and follow‐up visits would help prevent abuse. One prescriber states that he typically says to his patients, “Let’s not pay for a pound of this stuff until we know it works. I’ll write you enough for ten days and let me see you back in a week and we will look at what we want to prescribe from there. Call me if you have any problems.”175 He says that he does “the same sort of thing with refills.”175

Patients with complex psychiatric symptoms According to Dr. William Bobo, M.D. (Mayo Clinic psychiatrist), managing patients with bipolar‐ and coexisting anxiety disorders over the long term is a dilemma for clinicians, and it is controversial.103 "Higher illness complexity appeared to be the major driver of benzodiazepine use in patients with bipolar I and II disorder, and using benzodiazepines with more established treatments may represent clinicians' best efforts to bring complex psychiatric symptoms under better control, but that has to be weighed against the risks and limited evidence supporting long‐term benzodiazepine treatment. My recommendation would be to exercise caution. Not every patient is guaranteed a worse or no outcome with these drugs, but we need to better understand for which patients they may be safe and effective." NOTE: Use of benzodiazepines in bipolar is an off‐label use. Lexicomp summarizes guideline recommendations for this use as follows: “APA guidelines182 for the treatment of patients with bipolar disorder suggest that the use of benzodiazepines, such as clonazepam, in sedative doses may be useful short‐term as adjunctive therapy when used with traditional mood‐stabilizing agents. CANMAT guidelines183 for the management of patients with bipolar disorder recommend against the use of benzodiazepines as monotherapy, but suggest they may be useful adjunctive therapy for the sedation of acutely agitated patients. Similarly, WFSBP guidelines184 for the treatment of acute mania in bipolar disorder recommend benzodiazepines as adjunctive therapy to target anxiety and insomnia in patients taking mood‐stabilizing agents.”30

Adverse effects & abuse/dependence potential: The most common drug‐related adverse reactions relate to the sedative effects of the medication class. Evidence available for differences in adverse event rates between the benzodiazepine agents is limited. The benzodiazepines have varying pharmacokinetic profiles which may contribute to differences in adverse event rates. Rapidly absorbed benzodiazepine agents have the most rapid onset of action but also the greatest abuse/dependence potential. Long‐acting benzodiazepine agents are associated with accumulation which may result in sedation, cognitive impairment and psychomotor retardation. Short‐acting benzodiazepine agents are associated with increased anxiety, insomnia and rebound effects upon discontinuation. All benzodiazepine agents are associated with dependence or tolerance with long‐term use. Benzodiazepine therapy should be discontinued by a slow taper to avoid withdrawal effects. Adverse events may be reduced by using the smallest dose and shortest duration possible and by titrating the dose gradually. Refer to safety section for additional information.

30

Duplication of therapy: Generally, use of two or more benzodiazepines at the same time is not indicated. In rare situations, differences in pharmacokinetic parameters may make use of two agents for different situations in the same patient a reasonable therapeutic choice (e.g. epilepsy and insomnia).

Challenges/Food for thought: Patients already receiving both benzodiazepines and opioids (should be avoided; CDC

recommendations). It is the responsibility of physicians to communicate the risks of overdose with each patient and discuss with other providers to determine whether both medications are indicated.185

According to Dr. William Bobo, M.D. (Mayo Clinic psychiatrist), “outpatient doctors often inherit patients discharged from the hospital on benzodiazepines, and there is no clear evidence to guide decisions about continuing or stopping these drugs.”103 Given that benzodiazepines should only be used short‐term and that alternatives are available, continued benzodiazepine use should rather be the exception than the norm, considering alternatives if appropriate.

“The individuals who intentionally abuse BZDs and those who inadvertently become dependent on them may differ substantially in clinical and demographic characteristics and possibly in response to treatment.”14

Consider consultation with behavioral health service experts/referring patients with complex conditions e.g. current or history of alcohol or drug use disorder, or concurrent severe psychiatric disorder.74

Prior authorization criteria of another plan186: Diagnosis/diagnosis code (e.g. anxiety disorder, acute muscle spasms, chronic muscle spasms,

epilepsy, seizure disorder, panic disorder, insomnia, or other) Specifically regarding insomnia: Have other insomnia related disorders been ruled out? (e.g., movement, breathing or psychiatric disorders and medication) For all diagnoses apart from epilepsy: What non‐pharmacological therapies has the recipient tried? (e.g. Applied Relaxation, Cognitive Behavioral, Mindfulness‐based Therapy, Muscle Relaxation, Worry Exposure, Short‐term Psychodynamic Psychotherapy, Stimulus Control, Sleep Hygiene Measures, Sleep restriction, or Other) AND for how long?

Whether the Controlled Substance Database (PMP) was checked on date of request and to list information (e.g. Date of Fill, Drug, Quantity, Day Supply, and Prescriber) for the most recent five (5) entries found on the PMP.

Whether the patient has a history of alcohol or drug abuse or dependence and whether the patient is in acute alcohol withdrawal.

Whether the patient is pregnant, because the use of benzodiazepines is contraindicated during pregnancy. Also, whether the patient has been counseled regarding risks to the fetus if becoming pregnant while receiving this medication.

31

UtahMedicaidUtilizationData Overall total utilization of benzodiazepines (Please refer to Appendix 2 for additional information)

Year Claims Patients

2014 102,134 20,501 2015 98,867 18,825 2016 93,798 17,783 2017 to date 22,326 9,383 TOTAL for this period 317,125 37,186

AlprazolamTablet

ClonazepamTablet

DiazepamTablet

LorazepamTablet

TemazepamCapsule

Number of claims 90,880 107,465 37,980 50,796 11,086

Number of patients 11,441 11,800 9,344 9,767 1,634

0

20,000

40,000

60,000

80,000

100,000

120,000

2014‐2017 Most commonly prescribed benzodiazepines

0

20,000

40,000

60,000

80,000

100,000

120,000

2014‐2017 Benzodiazepines claims (only showing those exceeding 1000 claims for this period)

32

This provides an indication of which products are potentially used for longer periods or in excessive quantities based on number of claims/patient. However, it does not provide details to draw accurate conclusions.

649 (185 male; 464 female) patients >64 years old received benzodiazepine prescriptions

A considerable number of patients are pediatric patients (5,580). Additional information on prescribers and diagnosis codes submitted in these patients have been included in appendix 2.

0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00

Ativan (lorazepam)Tablet

Midazolam Syrup

Klonopin (clonazepam)Tablet

Flurazepam Capsule

Diazepam Injection

Alprazolam Tablet Extended Release

Lorazepam Injection

Alprazolam Tablet

Diazepam Tablet

Temazepam Capsule

Clonazepam Tablet

Lorazepam Tablet

Triazolam Tablet

Alprazolam Tablet Dispersible

Tranxene (clorazepate) Tablet

Chlordiazepoxide Capsule

Clorazepate Tablet

Diazepam Oral Solution

Onfi (clobazam)Tablet

Oxazepam Capsule

Lorazepam Oral Concentrate

Clonazepam Tablet Dispersible

Midazolam Injection

Onfi (clobazam) Oral Suspension

Diazepam Oral Concentrate

Estazolam Tablet

Ratio of total claims/patients

0

1,500

3,000

4,500

6,000

7,500

<18 18‐24 25‐34 35‐44 45‐54 55‐64 >64

Number of patients

Age

Age & Sex

M

F

33

BENZODIAZEPINES ‐ ALL PATIENTSPRESCRIBER TYPE TOTAL CLAIMS 2014‐17

Optometrist 4 0.00%

Nurse Midwife 220 0.07%

Dentist 2,284 0.72%

Osteopath 29,866 9.42%

Physician Assistant 32,996 10.40%

Nurse Practitioner 63,217 19.93%

Physician 188,538 59.45%

TOTAL CLAIMS 317,125

0 25,000 50,000 75,000 100,000 125,000 150,000 175,000 200,000

Optometrist

Nurse Midwife

Dentist

Osteopath

Physician Assistant

Nurse Practioner

Physician

Number of claims

Prescribers (by credentials)

0 30,000 60,000 90,000 120,000 150,000 180,000 210,000

HepatologyProctology

ImmunologyGerontologyDermatology

Sleep MedicineOphthalmology

RadiologyUrology

RheumatologyOtorhinolaryngology

GastroenterologyCardiology

Infectious DiseaseHematology

AnesthesiologyEndocrinology

HospitalistGeneral Surgery

PulmonologyPain Management

OncologyNephrologyOrthopedics

Physical Medicine & RehabGeriatric Medicine

Obstetrics‐GynecologyEmergency Medicine

NeurologyPediatrics

Internal MedicinePsychiatry

Family Medicine

Number of claims

Prescribers by specialty

34

BENZODIAZEPINES ‐ ALL PATIENTSPRESCRIBER SPECIALTY TOTAL CLAIMS 2014‐17 Hepatology 1 0.00%

Proctology 4 0.00%

Immunology 8 0.00%

Gerontology 14 0.00%

Dermatology 37 0.01%

Sleep Medicine 68 0.02%

Ophthalmology 70 0.02%

Radiology 82 0.03%

Urology 180 0.06%

Rheumatology 186 0.06%

Otorhinolaryngology 252 0.08%

Gastroenterology 268 0.08%

Cardiology 280 0.09%

Infectious Disease 311 0.10%

Hematology 334 0.11%

Anesthesiology 342 0.11%

Endocrinology 369 0.12%

Hospitalist 471 0.15%

General Surgery 499 0.16%

Pulmonology 640 0.20%

Pain Management 649 0.20%

Oncology 936 0.30%

Nephrology 1,081 0.34%

Orthopedics 1,332 0.42%

Physical Medicine & Rehab 2,066 0.65%

Geriatric Medicine 2,492 0.79%

Obstetrics‐Gynecology 2,759 0.87%

Emergency Medicine 4,868 1.54%

Neurology 7,612 2.40%

Pediatrics 10,373 3.27%

Internal Medicine 23,566 7.43%

Psychiatry 52,433 16.53%

Family Medicine 202,542 63.87%

TOTAL CLAIMS 317,125 Appendix 3 contains information on: (Table number as listed in appendix listed first e.g. T15) T15. The number of patients exceeding proposed dose and duration limits for each product.

It is important to review the data in the table as it varies by product and benzodiazepine.

Overall, out of 37,186 patients, about 7% exceeded the proposed dose limits, and about 50% exceeded duration of use limits 12,791 (34%) received benzodiazepines for >4 months. Additional information can be found in appendix 3 for the number of patients exceeding longer durations. About 5.5% of claims exceeded the proposed dose limits.

T16. How many patients had diagnosis codes submitted for the following?

However, it is important to consider that there are several limitations when reviewing data based on diagnosis codes.

35

Diagnosis grouping Number of patients

A EPILEPSY/SEIZURES 5,570 (15%)

B ALCOHOL MISUSE 3,742 (10%)

C DRUG DEPENDENCE 11,657 (31%)

D DRUG ABUSE 5,289 (14%)

E BENZODIAZAPINE POISONING 820 (2%)

F OTHER POISONING 2,837 (8%)

G BENZODIAZAPINE ACCIDENTAL POISONING 213 (1%)

H OTHER ACCIDENTAL POISONING 1,445 (4%)

Information on these diagnoses were gathered to further explore benzodiazepine use:

because abuse of benzodiazepines is often associated with multiple‐substance abuse

to separate out patients with alcohol dependence related diagnoses that could have received higher doses. However, according to Susan Siegfried, “the higher maximum doses listed for alcohol withdrawal are almost exclusively prescribed on an inpatient basis, due to inherent risks.” Doses in critical illness/emergency care may also be different from usual practice.

to explore the number of patients who had experienced poisoning (including accidental)

T17. The number of patients that exceeded duration of use limits who had diagnosis codes submitted as described above and to compare whether these patients were at increased risk compared to the overall patient group (T16) in terms of the number of diagnosis codes submitted for poisoning and whether more of these patients had diagnosis codes submitted for any of the other categories. It is important to consider that excessive quantities also put other people at risk for overdose if shared etc. which would not be shown in this data.

Increased risk => higher percentages for dependence, abuse, and poisoning (double and more for abuse and poisoning compared to all patients which is very concerning; refer to table on next page)

T18. The number of patients that exceeded proposed dose limits that had diagnosis codes submitted

as described above to compare whether these patients were at increased risk compared to the overall patient group (T16) in terms of the number of diagnosis codes submitted for poisoning and whether more of these patients had diagnosis codes submitted for any of the other categories. “The doses of benzodiazepines taken by abusers are usually in excess of the recommended therapeutic dose.”7

Increased risk => higher percentages for dependence, abuse, and poisoning (also clearly much higher for abuse and poisoning compared to all patients; refer to table on next page).

T19. The top prescribers and how many of their patients and associated claims exceeded the

proposed quantity limits and duration of use.

Exceeding dose limit ‐ Claims: Some higher percentages (as high as 50% vs 5.5% ALL) Patients: Higher percentage of about 20‐40% for some (vs. 7% ALL)

Exceeding duration: Higher percentage of about 60‐80% (as high as 87% vs 50% ALL)

36

The table below is a comparison of overall percentages for diagnosis codes submitted for all patients, those exceeding recommended doses and those exceeding duration of use recommendations.

Epilepsy/ Seizures

Alcohol dependence

Drug dependence

Drug abuse

Benzo poisoning

Other poisoning

Accidental Benzo

poisoning

Accidental Other

poisoning

DX A DX B DX C DX D DX E DX F DX G DX H

All 14.98% 10.06% 31.35% 14.22% 2.21% 7.63% 0.57% 3.89%

Exceeding Dose ALL 25.49% 23.28% 55.54% 30.36% 5.70% 16.59% 2.10% 9.46%

Exceeding Dose FFS 24.72% 22.68% 54.39% 28.99% 5.29% 15.86% 2.30% 9.04%

Exceeding Duration

4 Months 18.07% 12.26% 43.25% 19.62% 3.84% 10.86% 1.13% 6.25%

6 Months 19.68% 12.34% 44.67% 19.79% 3.95% 11.07% 1.22% 6.64%

9 Months 21.13% 12.15% 45.86% 19.51% 3.92% 11.16% 1.20% 6.75%

1 Year 22.60% 11.63% 46.54% 18.86% 3.65% 10.81% 1.17% 6.86%

18 Months 24.61% 11.30% 45.29% 17.55% 3.27% 10.16% 1.16% 6.87%

2 Years 26.60% 10.16% 43.57% 16.35% 3.27% 9.77% 1.22% 6.59%

3 Years 26.93% 8.40% 39.58% 14.58% 2.99% 9.27% 1.25% 5.79%

4 Years 36.88% 7.50% 36.88% 16.25% 3.13% 7.50% 1.25% 6.25%

When comparing percentages of diagnosis codes by product, it is also clear that patients who exceeded recommended doses and duration, also had a higher percentage of diagnosis codes submitted for abuse and poisoning.

37

Duplicative therapy As mentioned before, use of two or more benzodiazepines at the same time is likely inappropriate and filling prescriptions for benzodiazepines on the same day or within the same month indicates potential misuse/abuse. This occurred on thousands of occasions and the tables below contains additional information on this issue. SAME DAY THERAPY

Same Day Fill: Total Occurrences 6,602

Same Day Fill: Total Unique Patients 1,658

Same Day and Same Prescriber: Total Occurrences 5,700

Same Day and Same Prescriber: Total Unique Patients 1,441

Patients: Same Prescriber, Different Agent 1,197

Patients: Same Prescriber, Different Agent and >1 Pharmacy 190

Patients: Same Prescriber, Same Agent, Different Dose 395

Patients: Same Prescriber, Same Agent, Different Dose and >1 Pharmacy 52

Same Day and Different Prescriber: Total Occurrences 902

Same Day and Different Prescriber: Total Unique Patients 337

Patients: Different Prescriber, Different Agent 282

Patients: Different Prescriber, Different Agent and >1 Pharmacy 11

Patients: Different Prescriber, Same Agent, Different Dose 67

Patients: Different Prescriber, Same Agent, Different Dose and >1 Pharmacy 7

SAME MONTH THERAPY

Same Month Fill: Total Occurrences 20,959

Same Month Fill: Total Unique Patients 7,334

Same Month and Same Prescriber: Total Occurrences 15,095

Same Month and Same Prescriber: Total Unique Patients 6,174

Patients: Same Prescriber, Different Agent 4,812

Patients: Same Prescriber, Different Agent and >1 Pharmacy 637

Patients: Same Prescriber, Same Agent, Different Dose 1,962

Patients: Same Prescriber, Same Agent, Different Dose and >1 Pharmacy 158

Same Month and Different Prescriber: Total Occurrences 5,864

Same Month and Different Prescriber: Total Unique Patients 1,390

Patients: Different Prescriber, Different Agent 963

Patients: Different Prescriber, Different Agent and >1 Pharmacy 56

Patients: Different Prescriber, Same Agent, Different Dose 376

Patients: Different Prescriber, Same Agent, Different Dose and >1 Pharmacy 29

38

Conclusions Benzodiazepines are overprescribed (excessive quantities and long‐term use) and this overuse is not supported by the evidence. Clinical guidelines do not recommend benzodiazepines as first line treatment in anxiety or insomnia. According to the guidelines for treating anxiety disorders and insomnia disorders, very little evidence supports the use of benzodiazepine agents, even as second line agents. If used to treat anxiety or insomnia, benzodiazepines should be used at the lowest effective dose and on a short‐term basis (≤ 4 months) only. Inappropriate prescribing has led to excessive long‐term use and clinicians and patient resistance to treatment discontinuation. Due to limited evidence and safety concerns, it is recommended to limit benzodiazepine use in the elderly, in children, and in patients with a history of substance abuse. In general, all benzodiazepines have similar adverse events but the rates of these events may differ depending on their individual pharmacokinetic profiles. Overall, benzodiazepines should be used at the lowest effective dose for the shortest time possible with a comprehensive treatment plan and careful follow‐up. Review of the Utah Medicaid Utilization data raised many concerns regarding benzodiazepine use. Thousands of patients are receiving benzodiazepines in doses and durations that exceed recommendations. Many patients receiving benzodiazepines had diagnosis codes submitted for abuse and poisoning/overdoses (a much higher percentages of those that exceeded limits/duration had these diagnosis codes submitted). Duplicative therapy is also of particular concern. We therefore have a long way to go on educating prescribers about evidence‐based prescribing, implementing measures to ensure safe doses and durations are employed, and to help channel people with problematic drug use to get the help they need. A lot of emphasis has been put on opioid misuse and abuse. Adverse consequences of inappropriate benzodiazepine use and abuse are major problems that need to be addressed.

39

Appendix1–DruginformationTable 6. Comparison of Benzodiazepine Agents11,13,30,71,72,187 Product Route of

Administration Available Doses Labeled Uses Unlabeled Uses Active

Metabolite Generic Available

Adult Oral Dosage Range & Maximum Oral dose (adults)

Alprazolam (Xanax® and Xanax XR®)

Oral Oral tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg 0.5 mg XR, 1 mg XR, 2 mg XR, 3 mg XR Oral solution: 1mg/mL (30 mL)

Treatment of anxiety disorders, panic disorder and anxiety associated with depression.

Treatment of anxiety in children.

No Yes 0.75 to 6 mg daily Prescribing Limits/Maximum: Anxiety Disorders: 4 mg daily Panic Disorder: 10 mg daily.

Chlordiazepoxide (Librium®, others)

Oral, IM, IV Oral tablets: 5 mg, 10 mg, 25 mg

Treatment of anxiety disorders, withdrawal symptoms of acute alcoholism and preoperative apprehension/anxiety.

N/A Yes Yes 15 to 300 mg daily Mild to moderate anxiety: 5–10 mg 3 or 4 times daily Severe anxiety, 20–25 mg 3 or 4 times daily. Maximum: Acute alcohol withdrawal: 300 mg daily

Chlordiazepoxide/ Amitriptyline (Limbitrol®)

Oral 5/12.5 mg, 10/25 mg Treatment of anxiety, agitation and depression.

N/A Yes Yes 2 to 6 tablets daily in one or more divided doses. Maximum daily dose: amitriptyline 150 mg/ chlordiazepoxide 60 mg.

Clidinium/ Chlordiazepoxide (Librax®)

Oral 2.5/5 mg Treatment of irritable bowel syndrome and adjunct treatment of peptic ulcer.

N/A Yes Yes 1 to 2 capsules 3 to 4 times daily

Clobazam (Onfi™) Oral 5 mg, 10 mg, 20 mg Adjunctive treatment of seizures associated with Lennox‐Gastaut syndrome

Catamenial epilepsy; epilepsy (monotherapy)

Yes No 5 to 40 mg daily Maximum: Adjunctive Therapy in Lennox‐Gastaut Syndrome: 20 mg daily in those weighing ≤30 kg and 40 mg daily in those weighing >30 kg

Clonazepam (Klonopin®)

Oral 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg

Treatment of petit mal variant (Lennox‐Gastaut), akinetic and myoclonic seizures; petit mal (absence) seizures unresponsive to succimides; and panic disorder.

Treatment of restless leg syndrome, neuralgia, multifocal tic disorder, parkinsonian dysarthria, bipolar disorder, burning mouth syndrome and adjunct therapy for schizophrenia.

No Yes 1 to 20 mg daily Maximum: Seizure Disorders: 20 mg daily Panic Disorder: 4 mg daily

40

Product Route of Administration

Available Doses Labeled Uses Unlabeled Uses Active Metabolite

Generic Available

Adult Oral Dosage Range & Maximum Oral dose (adults)

Clorazepate (Traxene®, others)

Oral 3.75 mg, 7.5 mg, 15 mg Treatment of anxiety disorders, ethanol withdrawal and adjunct in management of partial seizures.

N/A Yes Yes 15 to 90 mg daily Maximum: Alcohol Withdrawal: 90 mg daily Adjunctive Therapy for Partial Seizures: 90 mg daily

Diazepam (Valium®, others)

Oral, IM, IV, Rectal

Oral tablets: 2 mg, 5 mg, 10 mg Oral solution: 1mg/mL (5 mL, 500 mL), 5mg/mL (30 mL) Injection solution: 5mg/mL (2 mL, 10 mL) Rectal Gel: 5 mg, 10 mg, 20 mg

Oral and injection: Treatment of anxiety disorders, ethanol withdrawal, skeletal muscle relaxant, convulsive disorders and sedation/amnesia. Rectal gel: Treatment of refractory epilepsy patients.

Treatment of panic disorders and spasticity in children with cerebral palsy.

Yes Yes 4 to 40 mg daily Maximum: Rectal: Maximum recommended frequency for administration by caregivers outside hospital is 1 treatment course every 5 days and 5 treatment courses per month.

Estazolam (Prosom®)

Oral 1 mg, 2 mg Short‐term treatment of insomnia.

N/A No Yes 1 to 2 mg

Flurazepam (Dalmane®)

Oral 15 mg, 30 mg Short‐term treatment of insomnia.

N/A Yes Yes 15 to 30 mg

Lorazepam (Ativan®)

Oral, IM, IV Oral tablets: 0.5 mg, 1 mg, 2 mg Oral solution: 2mg/mL (30 mL) Injection solution: 2mg/mL (1 mL, 10 mL), 4mg/mL (1mL, 10 mL)

Oral: Treatment of anxiety disorders and short‐term management of anxiety associated with depressive symptoms. I.V.: Status epilepticus, amnesia and sedation.

Treatment of ethanol withdrawal, insomnia, psychogenic catatonia, partial complex seizures, agitation and as antiemetic adjunct.

No Yes 2 to 6 mg daily

Midazolam (Versed®)

Oral, IV, IM Oral solution: 2mg/mL (118 mL) Injection solution: 1mg/mL (2 mL, 5 mL, 10 mL), 5mg/mL (1 mL, 2 mL, 5 mL, 10 mL)

For preoperative, preprocedural, or ICU sedation and induction/maintenance of general anesthesia.

Treatment of anxiety and status epilepticus.

Yes Yes N/A

Oxazepam (Serax®)

Oral 10 mg, 15 mg, 30 mg Treatment of anxiety and ethanol withdrawal.

Management of simple partial seizures and as a hypnotic.

No Yes 30 to 120 mg daily

Quazepam (Doral®)

Oral 15 mg Treatment of insomnia. N/A Yes No 7.5 to 15 mg

Temazepam (Restoril®)

Oral 7.5 mg, 15 mg, 22.5 mg, 30 mg

Short‐term treatment of insomnia.

Treatment of anxiety, panic attacks and as an adjunct in the treatment of depression.

No Yes; excluding 7.5 mg and 22.5 mg doses

7.5 to 30 mg

Triazolam (Halcion®)

Oral 0.125 mg, 0.25 mg Short‐term treatment of insomnia.

N/A No Yes 0.125 to 0.25 mg Maximum: 0.5 mg daily

Key: IM = intramuscular, IV = intravenous

41

Table 7. Warnings and Precautions for the Benzodiazepine Agents188,189 Warnings Precautions Other Considerations

ALERT: US Boxed Warning Risks from concomitant use with opioids:

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory

depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for

whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and

symptoms of respiratory depression and sedation.

Contraindications: Hypersensitivity to agent or any component of the formulation (cross‐sensitivity

with other benzodiazepines may exist).

Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Breakthrough anxiety: At the end of dosing interval, breakthrough anxiety may occur. Tolerance: Alprazolam has a short half‐life for a benzodiazepine and the duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance does not develop to the anxiolytic effects. Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect. Withdrawal: Rebound or withdrawal symptoms, including seizures, may occur following abrupt discontinuation or large decreases in dose (more common in adult patients receiving >4 mg/day or prolonged treatment); the risk of seizures appears to be greatest 24 to 72 hours following discontinuation of therapy. Use caution when reducing dose or withdrawing therapy; decrease slowly (eg, ≤0.5 mg every 3 days in adults) and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long‐term benzodiazepine therapy. Use with caution: in patients with depression, particularly if suicidal risk may be present; in patients with a history of drug abuse or acute alcoholism; in patients with hepatic impairment; in patients with porphyria; in patients with renal impairment; in patients with respiratory disease; in debilitated patients; active metabolites with extended half‐lives may lead to delayed accumulation and adverse effects; in patients who are at risk of falls; in children. Drug‐drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Benzodiazepines have been associated with anterograde amnesia. Benzodiazepines may cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving); Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated. Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients

Alprazolam: Contraindicated in acute narrow‐angle glaucoma; concurrent use with ketoconazole, itraconazole, or other potent CYP3A4 inhibitors. Chlordiazepoxide: Use with caution in patients with an impaired gag reflex. Clonazepam: Contraindicated in significant liver disease and acute narrow‐angle glaucoma; Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; Use with caution in patients with porphyria, may have a porphyrogenic effect. Clorazepate: Contraindicated in acute narrow‐angle glaucoma and Myasthenia gravis; Use with caution in the elderly, dosage adjustment recommended. Diazepam: The FDA is alerting health care providers and emergency responders that certain lots of CANA (diazepam) autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs; acute narrow‐angle glaucoma; Contraindicated in untreated open‐angle glaucoma, infants <6 months of age (oral), myasthenia gravis, severe respiratory impairment, severe hepatic impairment, sleep apnea syndrome; When used as an adjunct in treating convulsive disorders, an increase in frequency/severity of tonic‐clonic seizures may occur and require dose adjustment of anticonvulsant, abrupt withdrawal may result in a temporary increase in the frequency and/or severity of seizures; Use with caution in patients with an impaired gag reflex and in obese patients as diazepam may have prolonged action when discontinued in obese patients; Psychotic patients: Use of diazepam is not recommended in place of appropriate therapy. Lorazepam: Contraindicated in acute narrow‐angle glaucoma, sleep apnea (parenteral), intra‐arterial injection of parenteral formulation, severe respiratory insufficiency (except during mechanical ventilation); Psychiatric disorders: Preexisting depression may emerge or worsen during therapy, not recommended for use in primary depressive or psychotic disorders, should not be used in patients at risk for suicide without adequate antidepressant treatment; Use with caution in patients with an impaired gag reflex; Appropriate use: as a hypnotic, should be used only after evaluation of potential causes of sleep disturbance, failure of sleep disturbance to resolve after 7 to 10 days may indicate psychiatric or medical illness, a worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation. Oxazepam: May cause hypotension (rare), use with caution in patients with cardiovascular or cerebrovascular disease, or in patients who would not tolerate transient decreases in blood pressure; Use with caution in patients with an impaired gag reflex; Relative to other benzodiazepines, oxazepam possesses a short half‐life and lacks an active metabolite which may be preferable in the elderly if benzodiazepine use is required for anxiety.

Table 8. Pharmacokinetics Properties of the Benzodiazepine Agents11,13,30,71,72 Product Route of

Administration Absorption Distribution t½, hours Metabolism Active

Metabolite Elimination

ANXIOLYTIC

Alprazolam Oral Readily absorbed; Extended release: Slower relative to immediate release formulation resulting in a concentration that is maintained 5 to 11 hours after dosing; rate increased following night time dosing (versus morning dosing) Bioavailability: Immediate release: 84% to 92%; Extended release: 90%

Immediate release: Vd: 0.84 to 1.42 L/kg Protein binding: 80%; primarily to albumin

6.3‐26.9 Hepatic via CYP3A4; forms two active metabolites (4‐hydroxyalprazolam and α‐hydroxyalprazolam [about half as active as alprazolam]) and an inactive metabolite benzophenone metabolite, however, the active metabolites are unlikely to contribute to much of the pharmacologic effects because of their low concentrations and lesser potencies.

No Urine (as unchanged drug and metabolites)

Chlordiazepoxide Oral, IM, IV Well absorbed: peak concentrations 1‐2 hours after administration; rate of absorption is age‐related and tends to be delayed in the elderly.

Vd: 3.3 L/kg Protein binding: 96%

18‐96 Extensively hepatic to desmethyldiazepam (active and long‐acting), desmethylchlordiazepoxide, and demoxepam

Yes Urine (minimal as unchanged drug)

Clonazepam Oral Rapidly and completely absorbed Onset of action: ~20 to 40 minutes Bioavailability: ~90%

Children: Vd: 1.5 to 3 L/kg; Adults: Vd: 1.5 to 64.4 L/kg Protein binding: ~85%

18‐50 Extensively hepatic via glucuronide and sulfate conjugation; undergoes nitroreduction to 7‐aminoclonazepam, followed by acetylation to 7‐acetamidoclonazepam; nitroreduction and acetylation are via cytochrome P450 enzyme system; metabolites undergo glucuronide and sulfate conjugation

No Urine (<2% as unchanged drug); metabolites excreted as glucuronide or sulfate conjugates

Clorazepate Oral Rapidly absorbed following oral administration Bioavailability: 91%

Nordiazepam: Vd: 0.7 to 2.2 L/kg Protein binding: Nordiazepam: 97% to 98%

40‐120 Rapidly decarboxylated to nordiazepam (active) in acidic stomach prior to absorption; nordiazepam is hepatically hydroxylated by CYP 2C19 and CYP3A4 to oxazepam (active) and undergoes glucuronidation to form a glucuronide conjugate

Yes Urine (62% to 67%; primarily metabolites of conjugated oxazepam); feces (15% to 19%)

43


Absorption Distribution t½, hours Metabolism Active Metabolite

Elimination

Diazepam Oral, IM, IV, Rectal

Oral: Well absorbed (>90%); delayed and decreased when administered with a moderate fat meal Rectal: Well absorbed Bioavailability: IM: >90% Oral: >90% Rectal: 90%

IV: 1.2 L/kg (range: 0.6 to 2 L/kg) Oral: 1.1 L/kg (range: 0.6 to 1.8 L/kg Rectal: 1 L/kg Protein binding: Oral: Neonates: 84% to 86% Adults: 98% Rectal: 95% to 98%

40‐120a Hepatic; diazepam is N‐demethylated by CYP3A4 and 2C19 to the active metabolite N‐desmethyldiazepam, and is hydroxylated by CYP3A4 to the active metabolite temazepam. N‐desmethyldiazepam and temazepam are both further metabolized to oxazepam. Temazepam and oxazepam are largely eliminated by glucuronidation.

Yes Urine (predominantly as glucuronide conjugates)

Lorazepam Oral, IM, IV IM: Rapid and complete absorption Oral: Readily absorbed Onset of action: Anticonvulsant: IV: Within 10 minutes Hypnosis: IM: 20 to 30 minutes Sedation: IV: Within 2 to 3 minutes Bioavailability: Oral: 90%

IV: Vd: Neonates: 0.76 ± 0.37 L/kg (range: 0.14 to 1.3 L/kg) Pediatric patients: Crosses the blood brain barrier 5 months to < 3 years: 1.62 L/kg (range: 0.67 to 3.4 L/kg) 3 to <13 years: 1.5 L/kg (range: 0.49 to 3 L/kg) 13 to <18 years: 1.27 L/kg (range: 1 to 1.54 L/kg) Adults: 1.3 L/kg Protein binding: ~85% to 93%; free fraction may be significantly higher in elderly

10‐20 Hepatic; rapidly conjugated to lorazepam glucuronide (inactive)

No Urine (~88%; predominantly as inactive metabolites); feces (~7%)

Oxazepam Oral Slowly absorbed from the GI tract

Vd: 0.6 to 2 L/kg Protein binding: 96% to 98%

5‐20 Hepatic glucuronide conjugation to produce a single, major inactive metabolite (benzophenone)

No Urine (as inactive glucuronide conjugate)

44


Absorption Distribution t½, hours Metabolism Active Metabolite

Elimination

SEDATIVE/HYPNOTIC

Triazolam Oral Onset (oral): intermediate Vd: 0.6 to 1.7 L/kg Protein binding: 89%

1.5‐5.5 (Short)

Hepatic via CYP3A4 and glucuronide conjugation

No Urine (as unchanged drug and metabolites)

Temazepam Oral Onset: intermediate to slow


3.5‐18.4 (Intermediate)

Hepatic No Urine (as inactive metabolites)

Estazolam Oral N/A Vd: N/A Protein binding: 93%

10‐24 (Intermediate)

Hepatic via CYP3A4

No Urine (as unchanged drug and inactive metabolites) and feces (minimal)

Flurazepam Oral Onset: rapid to intermediate


Parent: 2.3 Metabolite: 74‐158 (long)

Hepatic Yes Urine (as active and inactive metabolites)

Quazepam Oral N/A Vd: 5‐8.6 L/kg Protein binding: >95%

Parent: 39 Metabolite: 39‐73 (long)

Hepatic via CYP3A4, 2C9, 2C19

Yes Urine (primarily metabolites) and feces

MISCELLANEOUS (used in seizure disorders/Lennox‐Gastaut syndrome)

Clobazam Oral N/A Vd: 100 L/kg Protein binding: 80‐90%

Parent: 36‐42 Metabolite: 71‐82

Hepatic via CYP3A4, 2C19, 2B6

Yes Urine (primarily as active and inactive metabolites)

Clonazepam See under anxiolytics

Clorazepate See under anxiolytics aHalf‐life of active metabolite, to which effects can be attributed. IM = intramuscular, IV = intravenous

Appendix2‐Additionaldata Table 11. All claims

BENZODIAZEPINES - ALL CLAIMS 2014 2015 2016 2017* ALL

AGENT PRODUCT CLAIMS PATIENTS CLAIMS PATIENTS CLAIMS PATIENTS CLAIMS PATIENTS CLAIMS PATIENTS

Alprazolam Alprazolam Oral Concentrate 0 0 0 0 1 1 0 0 1 1

Alprazolam Alprazolam Tablet 29,974 6,410 27,895 5,777 26,718 5,362 6,293 2,904 90,880 11,441

Alprazolam Alprazolam Tablet Dispersible 23 10 31 7 23 7 3 3 80 18

Alprazolam Alprazolam Tablet XR 447 113 406 104 358 79 84 37 1,295 227

Alprazolam Xanax Tablet 0 0 0 0 3 1 0 0 3 1

Chlordiazepoxide Chlordiazepoxide Capsule 572 293 564 310 616 323 157 107 1,909 814

Clobazam Onfi Oral Suspension 120 25 215 31 242 39 78 29 655 62

Clobazam Onfi Tablet 1,029 119 1,081 119 1,210 131 316 110 3,636 204

Clonazepam Clonazepam Tablet 34,436 6,729 33,642 6,160 31,697 5,639 7,690 3,150 107,465 11,800

Clonazepam Clonazepam Tablet Dispersible 384 116 497 136 575 150 158 72 1,614 315

Clonazepam Klonopin Tablet 30 5 12 2 11 1 2 1 55 5

Clorazepate Clorazepate Tablet 1,114 168 1,251 155 1,215 145 275 89 3,855 242

Clorazepate Tranxene Tablet 12 1 12 1 12 1 3 1 39 1

Diazepam Diazepam Injection 33 12 13 11 21 14 8 6 75 28

Diazepam Diazepam Oral Concentrate 8 8 7 5 18 15 8 8 41 29

Diazepam Diazepam Oral Solution 383 255 454 254 429 211 107 68 1,373 675

Diazepam Diazepam Tablet 12,278 4,090 12,177 3,866 10,966 3,508 2,559 1,375 37,980 9,344

Estazolam Estazolam Tablet 9 3 19 4 22 5 6 4 56 11

Flurazepam Flurazepam Capsule 128 26 89 18 60 14 15 7 292 41

Lorazepam Ativan Tablet 4 1 0 0 0 0 0 0 4 1

Lorazepam Lorazepam Injection 107 41 137 37 95 28 21 9 360 98

Lorazepam Lorazepam Oral Concentrate 174 87 176 87 226 111 71 40 647 253

Lorazepam Lorazepam Tablet 16,292 4,634 15,813 4,241 15,060 4,085 3,631 1,795 50,796 9,767

Midazolam Midazolam Injection 272 139 344 171 444 227 74 52 1,134 395

Midazolam Midazolam Syrup 235 192 151 125 84 72 15 13 485 382

Oxazepam Oxazepam Capsule 14 3 18 6 17 5 3 1 52 12

Temazepam Temazepam Capsule 3,669 819 3,437 720 3,304 688 676 318 11,086 1,634

Triazolam Triazolam Tablet 387 127 426 141 371 150 73 46 1,257 375

TOTAL 102,134 20,501 98,867 18,825 93,798 17,783 22,326 9,383 317,125 37,186 (Only products with claims/utilization are shown)

Table 12. FFS claims BENZODIAZEPINES - FFS CLAIMS 2014 2015 2016 2017* ALL


Alprazolam Alprazolam Tablet 11,917 3,098 9,711 2,486 8,235 1,945 1,748 855 31,611 5,488


Alprazolam Alprazolam Tablet Extended Release 153 43 125 38 89 27 20 9 387 92

Chlordiazepoxide Chlordiazepoxide Capsule 241 131 208 132 188 118 41 27 678 355


Clobazam Onfi Tablet 270 36 255 30 228 21 41 16 794 61

Clonazepam Clonazepam Tablet 13,007 3,066 11,332 2,542 9,573 1,965 2,124 901 36,036 5,509

Clonazepam Clonazepam Tablet Dispersible 114 27 119 34 149 40 41 17 423 82

Clorazepate Clorazepate Tablet 457 65 572 53 535 39 107 25 1,671 95

Clorazepate Tranxene Tablet 12 1 12 1 12 1 3 1 39 1



Diazepam Diazepam Oral Solution 90 67 116 63 83 36 21 15 310 158

Diazepam Diazepam Tablet 4,498 1,584 3,711 1,264 2,720 927 592 337 11,521 3,136




Lorazepam Lorazepam Tablet 7,018 2,168 6,011 1,788 5,248 1,480 1,287 603 19,564 4,400

Midazolam Midazolam Injection 27 8 21 5 70 46 12 10 130 60


Oxazepam Oxazepam Capsule 10 1 7 2 0 0 0 0 17 2

Temazepam Temazepam Capsule 1,279 374 1,082 281 831 211 162 78 3,354 695

Triazolam Triazolam Tablet 19 5 18 4 18 2 3 2 58 8

TOTAL 39,361 9,337 33,557 7,663 28,237 6,067 6,288 2,728 107,443 16,733

47

Table 13. Pediatric claims BENZODIAZEPINES - PEDIATRIC CLAIMS 2014 2015 2016 2017* ALL


Alprazolam Alprazolam Oral Concentrate 0 0 0 0 1 1 0 0 1 1

Alprazolam Alprazolam Tablet 295 158 272 157 312 146 68 45 947 416


Alprazolam Alprazolam Tablet Extended Release 1 1 11 4 4 4 0 0 16 8

Chlordiazepoxide Chlordiazepoxide Capsule 12 1 0 0 0 0 0 0 12 1


Clobazam Onfi Tablet 401 52 372 46 397 51 108 43 1,278 89

Clonazepam Clonazepam Tablet 1290 291 1246 271 1089 265 261 121 3,886 626

Clonazepam Clonazepam Tablet Dispersible 238 57 296 67 372 82 92 39 998 145

Clorazepate Clorazepate Tablet 302 64 278 47 228 50 55 25 863 91



Diazepam Diazepam Oral Solution 341 240 396 238 337 195 76 54 1,150 636

Diazepam Diazepam Tablet 1297 851 1129 776 944 690 194 163 3,564 2,235




Lorazepam Lorazepam Tablet 578 266 560 240 611 242 145 98 1,894 675

Midazolam Midazolam Injection 231 118 280 148 334 180 46 34 891 324


Temazepam Temazepam Capsule 42 15 51 18 62 15 10 5 165 42

Triazolam Triazolam Tablet 32 26 30 29 34 30 8 6 104 88

TOTAL 5,528 2,216 5,402 2,079 5,192 1,920 1,186 631 17,308 5,580

48

BENZODIAZEPINES - PEDIATRIC PATIENTS PRESCRIBER TYPE

TOTAL CLAIMS 2014-17

Nurse Midwife 5 0.03% Osteopath 744 4.30% Physician Assistant 1,196 6.91% Dentist 1,723 9.95% Nurse Practitioner 1,763 10.19% Physician 11,877 68.62% TOTAL CLAIMS 17,308

BENZODIAZEPINES - PEDIATRIC PATIENTS PRESCRIBER SPECIALTY

TOTAL CLAIMS 2014-17

Radiology 1 0.01% Hospitalist 1 0.01% Pain Management 1 0.01% Immunology 1 0.01% Oncology 1 0.01% Cardiology 2 0.01% Urology 3 0.02% Sleep Medicine 4 0.02% Infectious Disease 4 0.02% Dermatology 9 0.05% Gastroenterology 16 0.09% General Surgery 21 0.12% Obstetrics-Gynecology 22 0.13% Pulmonology 30 0.17% Ophthalmology 33 0.19% Otorhinolaryngology 35 0.20% Hematology 63 0.36% Endocrinology 75 0.43% Orthopedics 137 0.79% Neurology 145 0.84% Emergency Medicine 159 0.92% Internal Medicine 192 1.11% Physical Medicine & Rehab 264 1.53% Psychiatry 1,792 10.35% Pediatrics 6,778 39.16% Family Medicine 7,519 43.44% TOTAL CLAIMS 17,308

0 2,000 4,000 6,000 8,000 10,000 12,000

Nurse MidwifeOsteopath

Physician AssistantDentist

Nurse PractitionerPhysician

Number of claims

Prescribers (pediatric claims)

0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000

Radiology

Hospitalist

Pain Management

Immunology

Oncology

Cardiology

Urology

Sleep Medicine

Infectious Disease

Dermatology

Gastroenterology

General Surgery

Obstetrics‐Gynecology

Pulmonology

Ophthalmology

Otorhinolaryngology

Hematology

Endocrinology

Orthopedics

Neurology

Emergency Medicine

Internal Medicine

Physical Medicine & Rehab

Psychiatry

Pediatrics

Family Medicine

Prescriber specialty (pediatric claims)

49

Table 14. Number of pediatric patients by age and diagnosis codes BENZODIAZEPINES - PEDIATRIC PATIENTS

TOTAL PATIENTS 2014-2017

AGE* M F Total DX A PERCENT DX B PERCENT DX C PERCENT DX D PERCENT DX E PERCENT DX F PERCENT DX G PERCENT DX H PERCENT

0 27 15 42 16 38.10% 0 0.00% 5 11.90% 1 2.38% 1 2.38% 2 4.76% 1 2.38% 1 2.38%

1 67 43 110 57 51.82% 1 0.91% 15 13.64% 4 3.64% 0 0.00% 6 5.45% 1 0.91% 3 2.73%

2 74 63 137 80 58.39% 1 0.73% 3 2.19% 2 1.46% 0 0.00% 1 0.73% 0 0.00% 1 0.73%

3 80 79 159 76 47.80% 0 0.00% 4 2.52% 0 0.00% 1 0.63% 5 3.14% 0 0.00% 3 1.89%

4 122 142 264 64 24.24% 1 0.38% 2 0.76% 1 0.38% 0 0.00% 5 1.89% 1 0.38% 1 0.38%

5 188 195 383 66 17.23% 0 0.00% 4 1.04% 0 0.00% 0 0.00% 3 0.78% 1 0.26% 2 0.52%

6 252 218 470 70 14.89% 0 0.00% 4 0.85% 1 0.21% 0 0.00% 2 0.43% 0 0.00% 2 0.43%

7 206 177 383 74 19.32% 0 0.00% 1 0.26% 0 0.00% 0 0.00% 4 1.04% 0 0.00% 1 0.26%

8 173 159 332 59 17.77% 0 0.00% 3 0.90% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 1 0.30%

9 156 165 321 74 23.05% 0 0.00% 1 0.31% 0 0.00% 0 0.00% 9 2.80% 0 0.00% 9 2.80%

10 145 147 292 61 20.89% 0 0.00% 6 2.05% 0 0.00% 1 0.34% 3 1.03% 0 0.00% 2 0.68%

11 152 107 259 70 27.03% 0 0.00% 4 1.54% 1 0.39% 0 0.00% 3 1.16% 0 0.00% 2 0.77%

12 142 129 271 73 26.94% 1 0.37% 4 1.48% 4 1.48% 0 0.00% 6 2.21% 0 0.00% 1 0.37%

13 147 154 301 79 26.25% 0 0.00% 8 2.66% 6 1.99% 3 1.00% 12 3.99% 0 0.00% 5 1.66%

14 163 165 328 67 20.43% 3 0.91% 10 3.05% 14 4.27% 5 1.52% 20 6.10% 1 0.30% 8 2.44%

15 179 230 409 65 15.89% 10 2.44% 31 7.58% 37 9.05% 3 0.73% 26 6.36% 1 0.24% 12 2.93%

16 232 283 515 74 14.37% 23 4.47% 53 10.29% 56 10.87% 9 1.75% 49 9.51% 2 0.39% 13 2.52%

17 264 340 604 89 14.74% 29 4.80% 83 13.74% 84 13.91% 14 2.32% 46 7.62% 3 0.50% 18 2.98%

TOTAL 2,769 2,811

* Age at first claim.

50

Appendix3–Exceedingproposedlimitsanddurationofuse

Table 15. Exceeding proposed limits and duration of use BENZODIAZEPINES - ALL CLAIMS PROPOSED TOTAL EXCEED TOTAL EXCEED PROPOSED TOTAL EXCEED

AGENT PRODUCT LIMIT CLAIMS PROPOSED PERCENT PATIENTS PROPOSED PERCENT LIMIT PATIENTS PROPOSED PERCENT

Alprazolam ALPRAZOLAM CON 1 MG/ML >4 MG / DAY 1 0 0.00% 1 0 0.00% >12 WEEKS 1

Alprazolam ALPRAZOLAM TAB 0.25 ODT >4 MG / DAY 18 0 0.00% 4 0 0.00% >12 WEEKS 4

Alprazolam ALPRAZOLAM TAB 0.25MG >4 MG / DAY 6,915 1 0.01% 1,863 1 0.05% >12 WEEKS 1,863

Alprazolam ALPRAZOLAM TAB 0.5MG >4 MG / DAY 28,495 73 0.26% 5,588 33 0.59% >12 WEEKS 5,588

Alprazolam ALPRAZOLAM TAB 0.5MG ER >4 MG / DAY 173 0 0.00% 54 0 0.00% >12 WEEKS 54

Alprazolam ALPRAZOLAM TAB 0.5MG OD >4 MG / DAY 50 0 0.00% 11 0 0.00% >12 WEEKS 11

Alprazolam ALPRAZOLAM TAB 0.5MG XR >4 MG / DAY 30 0 0.00% 13 0 0.00% >12 WEEKS 13

Alprazolam ALPRAZOLAM TAB 1MG >4 MG / DAY 40,441 916 2.27% 4,948 275 5.56% >12 WEEKS 4,948

Alprazolam ALPRAZOLAM TAB 1MG ER >4 MG / DAY 404 3 0.74% 87 1 1.15% >12 WEEKS 87

Alprazolam ALPRAZOLAM TAB 1MG ODT >4 MG / DAY 4 3 75.00% 2 1 50.00% >12 WEEKS 2

Alprazolam ALPRAZOLAM TAB 1MG XR >4 MG / DAY 143 4 2.80% 43 2 4.65% >12 WEEKS 43

Alprazolam ALPRAZOLAM TAB 2MG >4 MG / DAY 15,029 8,116 54.00% 1,422 802 56.40% >12 WEEKS 1,422


Alprazolam ALPRAZOLAM TAB 2MG ODT >4 MG / DAY 8 8 100.00% 1 1 100.00% >12 WEEKS 1




Alprazolam XANAX TAB 2MG >4 MG / DAY 3 0 0.00% 1 0 0.00% >12 WEEKS 1

TOTAL ALL 92,259 9,223 10.00% 11,525 1,076 9.34% 11,525 5,983 51.91%

TOTAL FFS 32,005 3,008 9.40% 5,534 506 9.14% 5,534 2,891 52.24%

Chlordiazepoxide CHLORDIAZEP CAP 10MG >100 MG / DAY 387 7 1.81% 218 4 1.83% >4

MONTHS 218

Chlordiazepoxide CHLORDIAZEP CAP 25MG >100 MG / DAY 1,367 369 26.99% 664 251 37.80% >4

MONTHS 664

Chlordiazepoxide CHLORDIAZEP CAP 5MG >100 MG / DAY 155 0 0.00% 49 0 0.00% >4

MONTHS 49

TOTAL ALL 1,909 376 19.70% 814 254 31.20% 814 240 29.48%

TOTAL FFS 678 141 20.80% 355 102 28.73% 355 101 28.45%

Clonazepam CLONAZEP ODT TAB 0.125MG >4 MG / DAY 452 0 0.00% 75 0 0.00% >12 WEEKS 75


51

BENZODIAZEPINES - ALL CLAIMS PROPOSED TOTAL EXCEED TOTAL EXCEED PROPOSED TOTAL EXCEED



Clonazepam CLONAZEP ODT TAB 1MG >4 MG / DAY 232 20 8.62% 37 1 2.70% >12 WEEKS 37

Clonazepam CLONAZEP ODT TAB 2MG >4 MG / DAY 13 6 46.15% 8 2 25.00% >12 WEEKS 8

Clonazepam CLONAZEPAM TAB 0.5MG >4 MG / DAY 36,702 21 0.06% 6,370 11 0.17% >12 WEEKS 6,370

Clonazepam CLONAZEPAM TAB 1MG >4 MG / DAY 56,869 661 1.16% 6,540 179 2.74% >12 WEEKS 6,540

Clonazepam CLONAZEPAM TAB 2MG >4 MG / DAY 13,894 4,941 35.56% 1,348 543 40.28% >12 WEEKS 1,348

Clonazepam KLONOPIN TAB 0.5MG >4 MG / DAY 28 0 0.00% 3 0 0.00% >12 WEEKS 3

Clonazepam KLONOPIN TAB 1MG >4 MG / DAY 27 0 0.00% 2 0 0.00% >12 WEEKS 2

TOTAL ALL 109,134 5,649 5.18% 11,970 710 5.93% 11,970 6,961 58.15%

TOTAL FFS 36,459 1,987 5.45% 5,550 338 6.09% 5,550 3,170 57.12%

Clorazepate CLORAZ DIPOT TAB 15MG >90 MG / DAY 604 12 1.99% 31 6 19.35% >4

MONTHS 31

Clorazepate CLORAZ DIPOT TAB 3.75MG >90 MG / DAY 1,937 0 0.00% 174 0 0.00% >4

MONTHS 174

Clorazepate CLORAZ DIPOT TAB 7.5MG >90 MG / DAY 1,314 2 0.15% 77 1 1.30% >4

MONTHS 77

Clorazepate TRANXENE T TAB 3.75MG >90 MG / DAY 29 0 0.00% 1 0 0.00% >4

MONTHS 1

Clorazepate TRANXENE T TAB 7.5MG >90 MG / DAY 10 0 0.00% 1 0 0.00% >4

MONTHS 1

TOTAL ALL 3,894 14 0.36% 243 6 2.47% 243 125 51.44%

TOTAL FFS 1,710 6 0.35% 96 3 3.13% 96 47 48.96%

Diazepam DIAZEPAM CON 5MG/ML >40 MG / DAY 41 1 2.44% 29 1 3.45% >16 WEEKS 29

Diazepam DIAZEPAM INJ 5MG/ML >40 MG / DAY 75 2 2.67% 28 2 7.14% >16 WEEKS 28

Diazepam DIAZEPAM SOL 1MG/ML >40 MG / DAY 1,358 1 0.07% 670 1 0.15% >16 WEEKS 670

Diazepam DIAZEPAM SOL 5MG/5ML >40 MG / DAY 15 0 0.00% 8 0 0.00% >16 WEEKS 8

Diazepam DIAZEPAM TAB 10MG >40 MG / DAY 14,534 256 1.76% 2,751 75 2.73% >16 WEEKS 2,751



TOTAL ALL 39,469 299 0.76% 10,018 110 1.10% 10,018 2,695 26.90%

TOTAL FFS 11,908 109 0.92% 3,308 47 1.42% 3,308 1,120 33.86%

Estazolam ESTAZOLAM TAB 1MG >2 MG / DAY 5 0 0.00% 4 0 0.00% >12 WEEKS 4

Estazolam ESTAZOLAM TAB 2MG >2 MG / DAY 51 1 1.96% 7 1 14.29% >12 WEEKS 7

TOTAL ALL 56 1 1.79% 11 1 9.09% 11 7 63.64%

52

BENZODIAZEPINES - ALL CLAIMS PROPOSED TOTAL EXCEED TOTAL EXCEED PROPOSED TOTAL EXCEED


TOTAL FFS 0 0 0.00% 0 0 0.00% 0 0 0.00%

Flurazepam FLURAZEPAM CAP 15MG >30 MG / DAY 50 0 0.00% 13 0 0.00% >1 MONTH 13

Flurazepam FLURAZEPAM CAP 30MG >30 MG / DAY 242 1 0.41% 30 1 3.33% >1 MONTH 30

TOTAL ALL 292 1 0.34% 41 1 2.44% 41 31 75.61%

TOTAL FFS 168 1 0.60% 20 1 5.00% 20 13 65.00%

Lorazepam ATIVAN TAB 2MG >6 MG / DAY 4 0 0.00% 1 0 0.00% >12 WEEKS 1

Lorazepam LORAZEPAM CON 2MG/ML >6 MG / DAY 647 109 16.85% 253 54 21.34% >12 WEEKS 253

Lorazepam LORAZEPAM INJ 2MG/ML >6 MG / DAY 360 80 22.22% 98 35 35.71% >12 WEEKS 98

Lorazepam LORAZEPAM TAB 0.5MG >6 MG / DAY 15,499 45 0.29% 4,018 29 0.72% >12 WEEKS 4,018

Lorazepam LORAZEPAM TAB 1MG >6 MG / DAY 28,318 240 0.85% 6,178 107 1.73% >12 WEEKS 6,178

Lorazepam LORAZEPAM TAB 2MG >6 MG / DAY 6,979 915 13.11% 1,115 210 18.83% >12 WEEKS 1,115

TOTAL ALL 51,807 1,389 2.68% 9,993 415 4.15% 9,993 4,026 40.29%

TOTAL FFS 19,935 504 2.53% 4,506 207 4.59% 4,506 1,847 40.99%

Oxazepam OXAZEPAM CAP 10MG >60 MG / DAY 7 1 14.29% 5 1 20.00% >12 WEEKS 5



TOTAL ALL 52 6 11.54% 12 5 41.67% 12 6 50.00%

TOTAL FFS 17 0 0.00% 2 0 0.00% 2 2 100.00%

Temazepam TEMAZEPAM CAP 15MG >30 MG / DAY 4,239 48 1.13% 958 12 1.25% >1 MONTH 958

Temazepam TEMAZEPAM CAP 22.5MG >30 MG / DAY 35 0 0.00% 8 0 0.00% >1 MONTH 8

Temazepam TEMAZEPAM CAP 30MG >30 MG / DAY 6,694 136 2.03% 867 31 3.58% >1 MONTH 867

Temazepam TEMAZEPAM CAP 7.5MG >30 MG / DAY 118 0 0.00% 31 0 0.00% >1 MONTH 31

TOTAL ALL 11,086 184 1.66% 1,634 42 2.57% 1,634 1,243 76.07%

TOTAL FFS 3,354 36 1.07% 695 15 2.16% 695 546 78.56%

Triazolam TRIAZOLAM TAB 0.125MG >0.5 MG / DAY 42 1 2.38% 20 1 5.00% >7 DAYS 20

Triazolam TRIAZOLAM TAB 0.25MG >0.5 MG / DAY 1,215 56 4.61% 361 43 11.91% >7 DAYS 361

TOTAL ALL 1,257 57 4.53% 375 44 11.73% 375 174 46.40%

TOTAL FFS 58 3 5.17% 8 1 12.50% 8 4 50.00%

TOTAL ALL BENZOS ALL PTS 311,215 17,199 5.53% 37,186 2,526 6.79% 37,186 18,756 50.44%

TOTAL ALL BENZOS FFS PTS 106,292 5,795 5.45% 16,733 1,173 7.01% 16,733 7,850 46.91%

53

Table 16. Diagnosis codes submitted A EPILEPSY/SEIZURES B ALCOHOL MISUSE C DRUG DEPENDENCE D DRUG ABUSE E BENZODIAZAPINE POISONING F OTHER POISONING G BENZODIAZAPINE ACCIDENTAL POISONING H OTHER ACCIDENTAL POISONING (definitions/list of diagnosis codes included in each category available on request)

BENZODIAZEPINES - ALL CLAIMS 2014 - 2017

AGENT PRODUCT CLAIMS PATIENTS DX A DX B DX C DX D DX E DX F DX G DX H

Alprazolam Alprazolam Oral Concentrate 1 1 1 100.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Alprazolam Alprazolam Tablet 90,880 11,441 1,307 11.42% 1,183 10.34% 4,432 38.74% 2,000 17.48% 384 3.36% 1,044 9.13% 105 0.92% 571 4.99%

Alprazolam Alprazolam Tablet Dispersible 80 18 5 27.78% 2 11.11% 5 27.78% 2 11.11% 1 5.56% 4 22.22% 2 11.11% 2 11.11%

Alprazolam Alprazolam Tablet Extended Release 1,295 227 34 14.98% 31 13.66% 106 46.70% 50 22.03% 12 5.29% 29 12.78% 5 2.20% 14 6.17%

Alprazolam Xanax Tablet 3 1 1 100.00% 0 0.00% 1 100.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Chlordiazepoxide Chlordiazepoxide Capsule 1,909 814 279 34.28% 651 79.98% 563 69.16% 348 42.75% 55 6.76% 220 27.03% 17 2.09% 90 11.06%

Clobazam Onfi Oral Suspension 655 62 62 100.00% 0 0.00% 2 3.23% 0 0.00% 1 1.61% 3 4.84% 0 0.00% 0 0.00%

Clobazam Onfi Tablet 3,636 204 199 97.55% 3 1.47% 13 6.37% 4 1.96% 1 0.49% 7 3.43% 0 0.00% 3 1.47%

Clonazepam Clonazepam Tablet 107,465 11,800 1,878 15.92% 1,493 12.65% 4,679 39.65% 2,339 19.82% 443 3.75% 1,305 11.06% 109 0.92% 634 5.37%

Clonazepam Clonazepam Tablet Dispersible 1,614 315 138 43.81% 28 8.89% 68 21.59% 40 12.70% 8 2.54% 28 8.89% 3 0.95% 18 5.71%

Clonazepam Klonopin Tablet 55 5 3 60.00% 0 0.00% 1 20.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Clorazepate Clorazepate Tablet 3,855 242 168 69.42% 6 2.48% 33 13.64% 12 4.96% 0 0.00% 10 4.13% 0 0.00% 4 1.65%

Clorazepate Tranxene Tablet 39 1 1 100.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

54

BENZODIAZEPINES - ALL CLAIMS 2014 - 2017

AGENT PRODUCT CLAIMS PATIENTS DX A DX B DX C DX D DX E DX F DX G DX H

Diazepam Diazepam Injection 75 28 21 75.00% 3 10.71% 3 10.71% 3 10.71% 0 0.00% 3 10.71% 0 0.00% 1 3.57%

Diazepam Diazepam Oral Concentrate 41 29 16 55.17% 0 0.00% 2 6.90% 3 10.34% 0 0.00% 1 3.45% 1 3.45% 0 0.00%

Diazepam Diazepam Oral Solution 1,373 675 168 24.89% 1 0.15% 12 1.78% 6 0.89% 3 0.44% 17 2.52% 3 0.44% 13 1.93%

Diazepam Diazepam Tablet 37,980 9,344 1,203 12.87% 828 8.86% 2,995 32.05% 1,271 13.60% 206 2.20% 647 6.92% 54 0.58% 388 4.15%

Estazolam Estazolam Tablet 56 11 2 18.18% 1 9.09% 5 45.45% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 1 9.09%

Flurazepam Flurazepam Capsule 292 41 8 19.51% 7 17.07% 21 51.22% 5 12.20% 2 4.88% 8 19.51% 0 0.00% 3 7.32%

Lorazepam Ativan Tablet 4 1 1 100.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Lorazepam Lorazepam Injection 360 98 60 61.22% 15 15.31% 30 30.61% 11 11.22% 1 1.02% 10 10.20% 0 0.00% 3 3.06%

Lorazepam Lorazepam Oral Concentrate 647 253 119 47.04% 15 5.93% 50 19.76% 13 5.14% 4 1.58% 19 7.51% 1 0.40% 12 4.74%

Lorazepam Lorazepam Tablet 50,796 9,767 1,840 18.84% 1,352 13.84% 3,562 36.47% 1,724 17.65% 280 2.87% 988 10.12% 68 0.70% 511 5.23%

Midazolam Midazolam Injection 1,134 395 374 94.68% 4 1.01% 20 5.06% 10 2.53% 1 0.25% 18 4.56% 0 0.00% 10 2.53%

Midazolam Midazolam Syrup 485 382 14 3.66% 1 0.26% 2 0.52% 2 0.52% 0 0.00% 3 0.79% 0 0.00% 1 0.26%

Oxazepam Oxazepam Capsule 52 12 3 25.00% 5 41.67% 6 50.00% 4 33.33% 1 8.33% 3 25.00% 0 0.00% 2 16.67%

Temazepam Temazepam Capsule 11,086 1,634 263 16.10% 190 11.63% 633 38.74% 272 16.65% 64 3.92% 191 11.69% 18 1.10% 109 6.67%

Triazolam Triazolam Tablet 1,257 375 49 13.07% 28 7.47% 90 24.00% 57 15.20% 8 2.13% 27 7.20% 1 0.27% 17 4.53%

TOTALS 317,125 37,186 5,570 14.98% 3,742 10.06% 11,657 31.35% 5,289 14.22% 820 2.21% 2,837 7.63% 213 0.57% 1,445 3.89%

55

Table 17. Diagnosis codes submitted for those exceeding proposed/recommended duration of use (as defined above)

Duration (>) Patients Percent of Total

Any DX

Percent of PTS

DX A(Seiz)

Percentof PTS

DX B(Alc)

Percentof PTS

DX C(DEP)

Percentof PTS

DX D(ABU)

Percent of PTS

DX E(BNZ)

Percentof PTS

DX F(OTH)

Percentof PTS

DX G(BNZ)

Percentof PTS

DX H(OTH)

Percent of PTS

4 Months 12,791 34.40% 7554 59.06% 2311 18.07% 1568 12.26% 5532 43.25% 2509 19.62% 491 3.84% 1389 10.86% 145 1.13% 799 6.25%

6 Months 10,122 27.22% 6185 61.10% 1992 19.68% 1249 12.34% 4522 44.67% 2003 19.79% 400 3.95% 1120 11.07% 123 1.22% 672 6.64%

9 Months 7,571 20.36% 4754 62.79% 1600 21.13% 920 12.15% 3472 45.86% 1477 19.51% 297 3.92% 845 11.16% 91 1.20% 511 6.75%

1 Year 5,726 15.40% 3653 63.80% 1294 22.60% 666 11.63% 2665 46.54% 1080 18.86% 209 3.65% 619 10.81% 67 1.17% 393 6.86%

18 Months 3,612 9.71% 2319 64.20% 889 24.61% 408 11.30% 1636 45.29% 634 17.55% 118 3.27% 367 10.16% 42 1.16% 248 6.87%

2 Years 2,293 6.17% 1471 64.15% 610 26.60% 233 10.16% 999 43.57% 375 16.35% 75 3.27% 224 9.77% 28 1.22% 151 6.59%

3 Years 1,036 2.79% 645 62.26% 279 26.93% 87 8.40% 410 39.58% 151 14.58% 31 2.99% 96 9.27% 13 1.25% 60 5.79%

4 Years 160 0.43% 111 69.38% 59 36.88% 12 7.50% 59 36.88% 26 16.25% 5 3.13% 12 7.50% 2 1.25% 10 6.25%

TOTAL 37,186

56

Table 18. Diagnosis codes submitted for those exceeding proposed dose limits (as defined above)

TOTAL

PATIENTS EXCEED

MAX ADD Any DX Percentof PTS

DX A(All)

Percentof PTS

DX B(All)

Percentof PTS

DX C(DEP)

Percentof PTS

DX D(ABU)

Percent of PTS

Alprazolam ALL 11,525 1,076 759 70.54% 230 21.38% 163 15.15% 654 60.78% 354 32.90%

FFS 5,534 506 351 69.37% 100 19.76% 67 13.24% 300 59.29% 156 30.83%

Chlordiazepoxide ALL 814 254 247 97.24% 97 38.19% 227 89.37% 181 71.26% 110 43.31%

FFS 355 102 98 96.08% 41 40.20% 93 91.18% 71 69.61% 35 34.31%

Clonazepam ALL 11,970 710 522 73.52% 180 25.35% 126 17.75% 425 59.86% 241 33.94%

FFS 5,550 338 249 73.67% 85 25.15% 64 18.93% 193 57.10% 116 34.32%

Clorazepate ALL 243 6 6 100.00% 6 100.00% 0 0.00% 0 0.00% 0 0.00%

FFS 96 3 3 100.00% 3 100.00% 0 0.00% 0 0.00% 0 0.00%

Diazepam ALL 10,018 110 66 60.00% 31 28.18% 13 11.82% 46 41.82% 22 20.00%

FFS 3,308 47 28 59.57% 13 27.66% 6 12.77% 19 40.43% 8 17.02%

Estazolam ALL 11 1 1 100.00% 0 0.00% 0 0.00% 1 100.00% 0 0.00%

FFS 0 0 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Flurazepam ALL 41 1 1 100.00% 0 0.00% 0 0.00% 1 100.00% 0 0.00%

FFS 20 1 1 100.00% 0 0.00% 0 0.00% 1 100.00% 0 0.00%

Lorazepam ALL 9,993 415 294 70.84% 148 35.66% 95 22.89% 180 43.37% 99 23.86%

FFS 4,506 207 139 67.15% 66 31.88% 47 22.71% 85 41.06% 47 22.71%

Oxazepam ALL 12 5 4 80.00% 1 20.00% 4 80.00% 3 60.00% 2 40.00%

FFS 2 0 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Temazepam ALL 1,634 42 20 47.62% 5 11.90% 3 7.14% 19 45.24% 9 21.43%

FFS 695 15 4 26.67% 1 6.67% 1 6.67% 3 20.00% 2 13.33%

Triazolam ALL 375 44 11 25.00% 3 6.82% 1 2.27% 6 13.64% 3 6.82%

FFS 8 1 0 0.00% 0 0.00% 0 0.00% 0 0.00% 0 0.00%

TOTAL ALL 37,186 2,526 1,811 71.69% 644 25.49% 588 23.28% 1,403 55.54% 767 30.36%

FFS 16,733 1,173 835 71.18% 290 24.72% 266 22.68% 638 54.39% 340 28.99%

57

TOTAL

PATIENTS EXCEED

MAX ADD DX E

(BNZ) Percentof PTS

DX F(OTH)

Percentof PTS

DX G (BNZ)

Percentof PTS

DX H(OTH)

Percentof PTS

Alprazolam ALL 11,525 1,076 71 6.60% 172 15.99% 30 2.79% 118 10.97%

FFS 5,534 506 35 6.92% 74 14.62% 15 2.96% 50 9.88%

Chlordiazepoxide ALL 814 254 22 8.66% 78 30.71% 7 2.76% 26 10.24%

FFS 355 102 7 6.86% 23 22.55% 4 3.92% 12 11.76%

Clonazepam ALL 11,970 710 54 7.61% 129 18.17% 15 2.11% 73 10.28%

FFS 5,550 338 21 6.21% 65 19.23% 8 2.37% 35 10.36%

Clorazepate ALL 243 6 0 0.00% 0 0.00% 0 0.00% 0 0.00%

FFS 96 3 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Diazepam ALL 10,018 110 3 2.73% 11 10.00% 3 2.73% 8 7.27%

FFS 3,308 47 2 4.26% 3 6.38% 1 2.13% 3 6.38%

Estazolam ALL 11 1 0 0.00% 0 0.00% 0 0.00% 0 0.00%

FFS 0 0 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Flurazepam ALL 41 1 0 0.00% 0 0.00% 0 0.00% 0 0.00%

FFS 20 1 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Lorazepam ALL 9,993 415 10 2.41% 60 14.46% 4 0.96% 31 7.47%

FFS 4,506 207 5 2.42% 30 14.49% 2 0.97% 12 5.80%

Oxazepam ALL 12 5 1 20.00% 2 40.00% 0 0.00% 2 40.00%

FFS 2 0 0 0.00% 0 0.00% 0 0.00% 0 0.00%

Temazepam ALL 1,634 42 3 7.14% 6 14.29% 10 23.81% 2 4.76%

FFS 695 15 0 0.00% 1 6.67% 0 0.00% 0 0.00%

Triazolam ALL 375 44 1 2.27% 2 4.55% 0 0.00% 0 0.00%

FFS 8 1 0 0.00% 0 0.00% 0 0.00% 0 0.00%

TOTAL ALL 37,186 2,526 144 5.70% 419 16.59% 53 2.10% 239 9.46%

FFS 16,733 1,173 62 5.29% 186 15.86% 27 2.30% 106 9.04%

Table 19. Top prescribers and number of their claims and patients exceeding the proposed dose limits and duration of use

Type Specialty Claims Exceed ADD Percent Patients Exceed ADD Percent Exceed DUR Percent

Nurse Practitioner Psychiatry 5743 1015 17.67% 465 94 20.22% 360 77.42%

Physician Psychiatry 2431 431 17.73% 221 37 16.74% 170 76.92%



Osteopath Family Medicine 2247 85 3.78% 314 17 5.41% 229 72.93%


Physician Family Medicine 2004 20 1.00% 194 5 2.58% 129 66.49%



Nurse Practitioner Family Medicine 1702 10 0.59% 180 4 2.22% 125 69.44%






Physician Geriatric Medicine 1447 43 2.97% 247 13 5.26% 136 55.06%







Physician Internal Medicine 1165 97 8.33% 112 4 3.57% 78 69.64%



Osteopath Psychiatry 1095 2 0.18% 100 2 2.00% 77 77.00%




Physician Neurology 1044 0 0.00% 15 0 0.00% 13 86.67%

Physician Neurology 1005 0 0.00% 65 0 0.00% 51 78.46%

Physician Pediatrics 1003 39 3.89% 97 6 6.19% 33 34.02%






Physician Assistant Family Medicine 920 86 9.35% 172 25 14.53% 115 66.86%

Nurse Practitioner Nephrology 877 107 12.20% 170 17 10.00% 147 86.47%


59

Type Specialty Claims Exceed ADD Percent Patients Exceed ADD Percent Exceed DUR Percent




Physician Assistant Neurology 856 1 0.12% 66 1 1.52% 19 28.79%





Physician Pediatrics 773 2 0.26% 73 2 2.74% 24 32.88%






Dentist Family Medicine 716 0 0.00% 570 0 0.00% 0 0.00%



















Physician Geriatric Medicine 638 39 6.11% 127 19 14.96% 84 66.14%

Physician Internal Medicine 620 84 13.55% 44 6 13.64% 32 72.73%




References 1. Lowry F. Prescribing Benzodiazepines 'As Needed' May Promote Misuse. December 12, 2016.

http://www.medscape.com/viewarticle/873168#vp_2. 2. Prescribing benzodiazepines 'as needed' may promote misuse. December 14, 2016.

https://www.pharmacist.com/node/1082428. 3. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing Benzodiazepine

Prescriptions and Overdose Mortality in the United States, 1996‐2013. Am J Public Health. Apr 2016;106(4):686‐688.

4. SAMHSA. The TEDS Report. Admissions Reporting Benzodiazepine and Narcotic Pain Reliever Abuse at Treatment Entry. December 13, 2012. https://www.samhsa.gov/data/sites/default/files/BenzodiazepineAndNarcoticPainRelieverAbuse/BenzodiazepineAndNarcoticPainRelieverAbuse/BenzodiazepineAndNarcoticPainRelieverAbuse.htm.

5. Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug prescribing in the United States: extent, costs, and expenditures. J Clin Psychopharmacol. Feb 2011;31(1):1‐3.

6. Johnson B, Streltzer J. Risks associated with long‐term benzodiazepine use. Am Fam Physician. Aug 15 2013;88(4):224‐226.

7. Drug Enforcement Administration. Office of Diversion Control. BENZODIAZEPINES (Street Names: Benzos, Downers, Nerve Pills, Tranks). January 2013. https://www.deadiversion.usdoj.gov/drug_chem_info/benzo.pdf.

8. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. Jul 2010;71(7):839‐854.

9. NIH State‐of‐the‐Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. Jun 13‐15 2005;22(2):1‐30.

10. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. Feb 2015;72(2):136‐142.

11. Charney DS, Mihic SJ, Haris RA. Chapter 16. Hypnotics and Sedatives. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11e. New York, NY: McGraw‐Hill Medical Publishing.

12. Sternbach LH. The benzodiazepine story. J Psychoactive Drugs. Jan‐Jun 1983;15(1‐2):15‐17. 13. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug Information Handbook. 12th ed.

Hudson, OH: Lexi‐Comp; 2008. 14. Darker Catherine D, Sweeney Brion P, Barry Joe M, Farrell Michael F, Donnelly‐Swift E.

Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database of Systematic Reviews. 2015(5). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009652.pub2/abstract.

15. Zimmerman M, Chelminski I, Young D. On the threshold of disorder: a study of the impact of the DSM‐IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. J Clin Psychiatry. Oct 2004;65(10):1400‐1405.

16. Zimmerman M, McGlinchey JB, Young D, Chelminski I. Diagnosing major depressive disorder I: A psychometric evaluation of the DSM‐IV symptom criteria. J Nerv Ment Dis. Mar 2006;194(3):158‐163.

17. O'Donnell JM, Shelton RC. Drug Therapy of Depression and Anxiety Disorders. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics 12th ed. New York, NY: McGraw‐Hill; 2011.

18. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. Sep 2012;21(3):169‐184.

61

19. NICE. Generalised anxiety disorder and panic disorder in adults: management NICE guidelines [CG113]. https://www.nice.org.uk/guidance/cg113/chapter/1‐Guidance.2011.

20. NICE. Social anxiety disorder: recognition, assessment and treatment NICE guidelines [CG159]. https://www.nice.org.uk/guidance/cg159/chapter/1‐recommendations2013.

21. Van Ameringen M, Mancini C, Patterson B, Simpson W. Pharmacotherapy for social anxiety disorder: an update. Isr J Psychiatry Relat Sci. 2009;46(1):53‐61.

22. Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. Jul 08 2009(3):CD005170.

23. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. Jul 2006;51(8 Suppl 2):9S‐91S.

24. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry. Jul;71(7):839‐854.

25. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report. Sleep. Nov 1 2006;29(11):1415‐1419.

26. Schutte‐Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. Oct 15 2008;4(5):487‐504.

27. American Psychiatric Association. Sleep‐Wake Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5).Arlington, VAAmerican Psychiatric Association. 2013.

28. National Guideline C. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. 2016; https://guidelines.gov/summaries/summary/50399/management‐of‐chronic‐insomnia‐disorder‐in‐adults‐a‐clinical‐practice‐guideline‐from‐the‐american‐college‐of‐physicians?q=benzodiazepine.

29. FreeCE. Desperate for Sleep: Pharmacotherapy Options for the Management of Insomnia. http://www.freece.com/freeCE/CECatalog_Details.aspx?ID=c37552a9‐c5ef‐474f‐8fb7‐11292f3f684e. Accessed 4 April 2017.

30. Lexicomp Online. http://online.lexi.com/lco/action/home;jsessionid=9e594b72eaa6cad5cb54bcc0962e?siteid=1.

31. Comparison of Insomnia Treatments. Vol 26(10):26100: Pharmacist's Letter/Prescriber's Letter; 2010.

32. Martin JL, Sainz‐Pardo M, Furukawa TA, Martin‐Sanchez E, Seoane T, Galan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta‐analysis of clinical trials. J Psychopharmacol. Sep 2007;21(7):774‐782.

33. Cohn JB, Wilcox CS. Long‐term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. Pharmacotherapy. Mar‐Apr 1984;4(2):93‐98.

34. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol. Jun 1984;4(3):125‐129.

35. Lapierre YD. Clinical and physiological assessment of chlorazepate, diazepam and placebo in anxious neurotics. Int J Clin Pharmacol Biopharm. Jun 1975;11(4):315‐322.

36. Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed‐dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. Apr 1992;12(2):96‐103.

37. Rickels K, Csanalosi I, Greisman P, et al. A controlled clinical trial of alprazolam for the treatment of anxiety. Am J Psychiatry. Jan 1983;140(1):82‐85.

38. Rickels K, Fox IL, Greenblatt DJ, Sandler KR, Schless A. Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry. Mar 1988;145(3):312‐317.

39. Rimon R, Kultalahti ER, Kalli A, et al. Alprazolam and oxazepam in the treatment of anxious out‐patients with depressive symptoms: a double‐blind multicenter study. Pharmacopsychiatry. May 1991;24(3):81‐84.

62

40. Schweizer E, Fox I, Case G, Rickels K. Lorazepam vs. alprazolam in the treatment of panic disorder. Psychopharmacol Bull. 1988;24(2):224‐227.

41. Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. Mar 1990;23(2):90‐93.

42. Vaisanen E, Jalkanen E. A double‐blind study of alprazolam and oxazepam in the treatment of anxiety. Acta Psychiatr Scand. May 1987;75(5):536‐541.

43. Allen RP, Mendels J, Nevins DB, Chernik DA, Hoddes E. Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J Clin Pharmacol. Oct 1987;27(10):768‐775.

44. Bliwise D, Seidel W, Greenblatt DJ, Dement W. Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. Am J Psychiatry. Feb 1984;141(2):191‐195.

45. Bonnet MH, Arand DL. The use of lorazepam TID for chronic insomnia. Int Clin Psychopharmacol. Mar 1999;14(2):81‐89.

46. Bowen AJ. Comparative efficacy of triazolam, flurazepam and placebo in out‐patients insomniacs. J Int Med Res. 1978;6(4):337‐342.

47. Cohn JB. Double‐blind crossover comparison of triazolam and lorazepam in the posthypnotic state. J Clin Psychiatry. Mar 1984;45(3):104‐107.

48. Costa ESJA, Acioli A, Naylor C, Jones Da Silva C, Ferreira I. Midazolam and triazolam in out‐patients: a double‐blind comparison of hypnotic efficacy. Br J Clin Pharmacol. 1983;16 Suppl 1:179S‐183S.

49. Erman MK, Loewy D, Scharf MB. Comparison of temazepam 7.5 mg with temazepam 15 mg for the treatment of transient insomnia. Curr Med Res Opin. Apr 2004;20(4):441‐449.

50. Fabre LF, Jr., Gross L, Pasigajen V, Metzler C. Multiclinic double‐blind comparison of triazolam and flurazepam for seven nights in outpatients with insomnia. J Clin Pharmacol. Jul 1977;17(7):402‐409.

51. Feldmeier C, Kapp W. Comparative clinical studies with midazolam, oxazepam and placebo. Br J Clin Pharmacol. 1983;16 Suppl 1:151S‐155S.

52. Gallais H, Casanova P, Fabregat H. Midazolam and oxazepam in the treatment of insomnia in hospitalized patients. Br J Clin Pharmacol. 1983;16 Suppl 1:145S‐149S.

53. Kales A, Bixler EO, Soldatos CR, Vela‐Bueno A, Jacoby JA, Kales JD. Quazepam and temazepam: effects of short‐ and intermediate‐term use and withdrawal. Clin Pharmacol Ther. Mar 1986;39(3):345‐352.

54. Kales A, Bixler EO, Vela‐Bueno A, Soldatos CR, Niklaus DE, Manfredi RL. Comparison of short and long half‐life benzodiazepine hypnotics: triazolam and quazepam. Clin Pharmacol Ther. Oct 1986;40(4):378‐386.

55. Kok LP, Tsoi WF. Comparison of midazolam, diazepam and placebo in the treatment of insomnia. Singapore Med J. Jun 1986;27(3):200‐203.

56. Kripke DF, Hauri P, Ancoli‐Israel S, Roth T. Sleep evaluation in chronic insomniacs during 14‐day use of flurazepam and midazolam. J Clin Psychopharmacol. Aug 1990;10(4 Suppl):32S‐43S.

57. Leibowitz M, Sunshine A. Long‐term hypnotic efficacy and safety of triazolam and flurazepam. J Clin Pharmacol. May‐Jun 1978;18(5‐6):302‐309.

58. Lupolover R, Ballmer U, Helcl J, Escher J, Pavletic B. Efficacy and safety of midazolam and oxazepam in insomniacs. Br J Clin Pharmacol. 1983;16 Suppl 1:139S‐143S.

59. MacPhail I, Ogilvie WA, Purvis CR. Comparison of diazepam and flurazepam in the treatment of insomnia in general practice. J Int Med Res. 1979;7(5):401‐403.

60. Mamelak M, Csima A, Price V. A comparative 25‐night sleep laboratory study on the effects of quazepam and triazolam on chronic insomniacs. J Clin Pharmacol. Feb‐Mar 1984;24(2‐3):65‐75.

61. McClure DJ, Walsh J, Chang H, Olah A, Wilson R, Pecknold JC. Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. J Clin Pharmacol. Jan 1988;28(1):52‐63.

62. Reeves RL. Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia. J Clin Pharmacol. May‐Jun 1977;17(5‐6):319‐323.

63

63. Roth T, Hauri P, Zorick F, Sateia M, Roehrs T, Kipp J. The effects of midazolam and temazepam on sleep and performance when administered in the middle of the night. J Clin Psychopharmacol. Apr 1985;5(2):66‐69.

64. Saletu B, Anderer P, Brandstatter N, et al. Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long‐ versus a short‐half‐life benzodiazepine (quazepam versus triazolam). Neuropsychobiology. 1994;29(2):69‐90.

65. Scharf MB. Feasibility of an every‐other‐night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo. J Clin Psychiatry. Jan 1993;54(1):33‐38.

66. Sunshine A. Comparison of the hypnotic activity of triazolam, flurazepam hydrochloride, and placebo. Clin Pharmacol Ther. May 1975;17(5):573‐577.

67. Vogel GW, Barker K, Gibbons P, Thurmond A. A comparison of the effects of flurazepam 30 mg and triazolam 0.5 mg on the sleep of insomniacs. Psychopharmacology (Berl). May 5 1976;47(1):81‐86.

68. Wang RI, Stockdale SL, Hieb E. Hypnotic efficacy of lorazepam and flurazepam. Clin Pharmacol Ther. Feb 1976;19(2):191‐195.

69. Substance Abuse and Mental Health Services Administration (SAMHSA) https://www.samhsa.gov/.

70. University of Maryland Center for Substance Abuse Research (CESAR) http://www.cesar.umd.edu/cesar/drugs/benzos.asp.

71. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Drug Information Handbook. 12th ed. Hudson, OH: Lexi‐Comp; 2011.

72. McEvoy GK, Snow EK, Kester L, Litvak K, Miller J, Welsh OH, eds. AHFS 2011 Drug Information. Bethesda, MD: American Society of Health‐System Pharmacists; 2011.

73. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. Nov 2015;63(11):2227‐2246.

74. Kaiser Permanente. Benzodiazepine and Z‐Drug Safety Guideline. August 2014. https://www.ghc.org/static/pdf/public/guidelines/benzo‐zdrug.pdf.

75. Falloon K, Arroll B, Elley CR, Fernando A, 3rd. The assessment and management of insomnia in primary care. BMJ.342:d2899.

76. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence‐based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. Nov;24(11):1577‐1601.

77. Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta‐analysis. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). Mar 2005;27(1):18‐24.

78. Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev. Jan 20 2015;1:CD007505.

79. Uzun S, Kozumplik O, Jakovljevic M, Sedic B. Side effects of treatment with benzodiazepines. Psychiatr Danub. Mar;22(1):90‐93.

80. Lader M, Petursson H. Rational use of anxiolytic/sedative drugs. Drugs. May 1983;25(5):514‐528. 81. Brasure M, MacDonald R, Fuchs E, et al. Management of Insomnia Disorder. Rockville (MD)2015. 82. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly:

who is at greatest risk? Arch Intern Med. Jul 26 2004;164(14):1567‐1572. 83. Bartlett G, Abrahamowicz M, Grad R, Sylvestre MP, Tamblyn R. Association between risk factors

for injurious falls and new benzodiazepine prescribing in elderly persons. BMC Fam Pract. Jan 06 2009;10:1.

84. Johnson B, Streltzer J. Benzodiazepine use and hip fractures in older adults. In reply. Am Fam Physician. Dec 01 2013;88(11):728.

85. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta‐analysis: I. Psychotropic drugs. J Am Geriatr Soc. Jan 1999;47(1):30‐39.

64

86. Salonoja M, Salminen M, Aarnio P, Vahlberg T, Kivela SL. One‐time counselling decreases the use of benzodiazepines and related drugs among community‐dwelling older persons. Age Ageing. May;39(3):313‐319.

87. Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict. Winter 2001;10(1):48‐68.

88. Movig KL, Mathijssen MP, Nagel PH, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev. Jul 2004;36(4):631‐636.

89. Smink BE, Egberts AC, Lusthof KJ, Uges DR, de Gier JJ. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs. Aug 2010;24(8):639‐653.

90. Billioti de Gage S, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. Bmj. Sep 27 2012;345:e6231.

91. Petursson H, Gudjonsson GH, Lader MH. Psychometric performance during withdrawal from long‐term benzodiazepine treatment. Psychopharmacology (Berl). 1983;81(4):345‐349.

92. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long‐term benzodiazepine use: a meta‐analysis. CNS Drugs. 2004;18(1):37‐48.

93. Fenton MC, Keyes KM, Martins SS, Hasin DS. The role of a prescription in anxiety medication use, abuse, and dependence. Am J Psychiatry. Oct 2010;167(10):1247‐1253.

94. Authier N, Balayssac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr. Nov 2009;67(6):408‐413.

95. UK Medicines Information (UKMi). What are the equivalent doses of oral benzodiazepines. 24 April 2012. https://www.sps.nhs.uk/articles/what‐are‐the‐equivalent‐doses‐of‐oral‐benzodiazepines/.

96. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case‐cohort study. Bmj. Jun 10 2015;350:h2698.

97. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. [ 8‐31‐2016 ]. https://www.fda.gov/Drugs/DrugSafety/ucm518473.htm.

98. Smink BE, Egberts AC, Lusthof KJ, Uges DR, de Gier JJ. The relationship between benzodiazepine use and traffic accidents: A systematic literature review. CNS Drugs. Aug 1;24(8):639‐653.

99. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. Sep 2004;3(5):485‐493.

100. Pomara N, Lee SH, Bruno D, et al. Adverse performance effects of acute lorazepam administration in elderly long‐term users: pharmacokinetic and clinical predictors. Prog Neuropsychopharmacol Biol Psychiatry. Jan 02 2015;56:129‐135.

101. Bernstein BE. Pediatric Bipolar Affective Disorder Treatment & Management, February 10, 2017. http://emedicine.medscape.com/article/913464‐treatment#d8.

102. WHO. Management of substance abuse. Lexicon of terminology. 2010. http://www.who.int/substance_abuse/terminology/who_lexicon/en/ (accessed 20 May 2010). .

103. Clinical updates: Long‐term adjunctive benzodiazepines may not improve outcomes in bipolar disorder. http://www.mayoclinic.org/medical‐professionals/clinical‐updates/psychiatry‐psychology/long‐term‐adjunctive‐benzodiazepines‐may‐not‐improve‐outcomes‐in‐bipolar‐disorder. Accessed 29 March 2017.

104. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive‐compulsive disorder and posttraumatic stress disorder in primary care. International journal of psychiatry in clinical practice. Jun 2012;16(2):77‐84.

105. Van Ameringen M, Allgulander C, Bandelow B, et al. WCA recommendations for the long‐term treatment of social phobia. CNS Spectr. Aug 2003;8(8 Suppl 1):40‐52.

106. Stein DJ, Bandelow B, Hollander E, et al. WCA Recommendations for the long‐term treatment of posttraumatic stress disorder. CNS Spectr. Aug 2003;8(8 Suppl 1):31‐39.

65

107. Pollack MH, Allgulander C, Bandelow B, et al. WCA recommendations for the long‐term treatment of panic disorder. CNS Spectr. Aug 2003;8(8 Suppl 1):17‐30.

108. Greist JH, Bandelow B, Hollander E, et al. WCA recommendations for the long‐term treatment of obsessive‐compulsive disorder in adults. CNS Spectr. Aug 2003;8(8 Suppl 1):7‐16.

109. Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long‐term treatment of generalized anxiety disorder. CNS Spectr. Aug 2003;8(8 Suppl 1):53‐61.

110. Zohar J. WCA recommendations for the long‐term treatment of anxiety disorders. CNS Spectr. Aug 2003;8(8 Suppl 1):5‐6.

111. Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. The American journal of psychiatry. Nov 2004;161(11 Suppl):3‐31.

112. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American Psychiatric A. Practice guideline for the treatment of patients with obsessive‐compulsive disorder. The American journal of psychiatry. Jul 2007;164(7 Suppl):5‐53.

113. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. The American journal of psychiatry. May 1998;155(5 Suppl):1‐34.

114. Practice parameter for the assessment and treatment of children and adolescents with obsessive‐compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry. Jan 2012;51(1):98‐113.

115. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain ‐ United States, 2016. MMWR Recomm Rep. 2016;65(1):1‐49.

116. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain‐‐United States, 2016. Jama. Apr 19 2016;315(15):1624‐1645.

117. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults‐‐an update for 2012: practice parameters with an evidence‐based systematic review and meta‐analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. Aug 01 2012;35(8):1039‐1062.

118. Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update. 6 July 2011. Addiction to benzodiazepines and codeine. https://www.gov.uk/drug‐safety‐update/addiction‐to‐benzodiazepines‐and‐codeine.

119. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Internal Medicine. Jun 2014;174(6):890‐898.

120. Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. Jama. May 02 2012;307(17):1801‐1802.

121. American Geriatrics Society. Choosing Wisely website. Five things physicians and patients should question. 2013 http://www.choosingwisely.org/wp‐content/uploads/2013/01/about_choosingwisely_fivethings.pdf.

122. NICE Guidance: Depression in adults: recognition and management (CG90). Published date: June 2016 https://www.nice.org.uk/donotdo/the‐following‐strategies‐should‐not‐be‐used‐routinely‐augmentation‐of‐an‐antidepressant‐with‐a‐benzodiazepine‐for‐more‐than‐2‐weeks‐as‐there‐is‐a‐risk‐of‐dependence‐augmentation‐of‐an‐antidepressant‐with‐buspirone‐carbamazepine‐lamotrigine‐or‐valproate‐as. Accessed 26 April 2017.

123. Canadian Agency for Drugs and Technologies in Health. Short‐ and long‐term use of benzodiazepines in patients with generalized anxiety disorder: a review of guidelines. 28 July 2014. https://www.cadth.ca/media/pdf/htis/dec‐2014/RC0567%20Limiting%20Benzodiazepines%20Final.pdf.

124. Canadian Agency for Drugs and Technologies in Health. Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost‐Effectiveness, and Guidelines January 2011.

66

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0063498/pdf/PubMedHealth_PMH0063498.pdf.

125. Canadian Agency for Drugs and Technologies in Health. Discontinuation Strategies for Patients with Long‐Term Benzodiazepine Use: Clinical Evidence and Guidelines. 22 January 2015. https://www.cadth.ca/sites/default/files/pdf/htis/jan‐2015/RA0726%20BZD%20Discontinuation%20Strategies%20Final.pdf.

126. Gould RL, Coulson MC, Patel N, Highton‐Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta‐analysis of randomised controlled trials. Br J Psychiatry. Feb 2014;204(2):98‐107.

127. Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert opinion on drug safety. Jul 2014;13(7):919‐934.

128. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long‐term use of benzodiazepines in primary care: a systematic review and meta‐analysis. The British journal of general practice : the journal of the Royal College of General Practitioners. Sep 2011;61(590):e573‐578.

129. Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long‐term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. Jun 2014;204(6):471‐479.

130. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behav Res Ther. Aug 2010;48(8):720‐727.

131. Bobes J, Rubio G, Teran A, et al. Pregabalin for the discontinuation of long‐term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. European psychiatry : the journal of the Association of European Psychiatrists. May 2012;27(4):301‐307.

132. Kawasaki SS, Jacapraro JS, Rastegar DA. Safety and effectiveness of a fixed‐dose phenobarbital protocol for inpatient benzodiazepine detoxification. J Subst Abuse Treat. Oct 2012;43(3):331‐334.

133. de Gier NA, Gorgels WJ, Lucassen PL, Oude Voshaar R, Mulder J, Zitman F. Discontinuation of long‐term benzodiazepine use: 10‐year follow‐up. Fam Pract. Jun 2011;28(3):253‐259.

134. Rubio G, Bobes J, Cervera G, et al. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long‐term benzodiazepine use. European addiction research. 2011;17(5):262‐270.

135. Saxon L, Borg S, Hiltunen AJ. Reduction of aggression during benzodiazepine withdrawal: effects of flumazenil. Pharmacol Biochem Behav. Aug 2010;96(2):148‐151.

136. Canadian Agency for Drugs and Technologies in Health. Developmental effects of in utero exposure to prescription drug abuse in infants and young children: harms. 5 November 2014. https://www.cadth.ca/sites/default/files/pdf/htis/nov‐2014/RB0745%20Drug%20Use%20in%20Pregnancy%20Final.pdf.

137. Tannenbaum C. Time efficient interventions by general practitioners curb benzodiazepine consumption among long‐term users. Evid Based Ment Health. Feb 2015;18(1):30.

138. Vicens C, Sempere E, Bejarano F, et al. Efficacy of two interventions on the discontinuation of benzodiazepines in long‐term users: 36‐month follow‐up of a cluster randomised trial in primary care. Br J Gen Pract. Feb 2016;66(643):e85‐91.

139. Brasure M, Fuchs E, MacDonald R, et al. Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. Jul 19 2016;165(2):113‐124.

140. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. Jul 19 2016;165(2):103‐112.

67

141. McCleery J, Cohen Daniel A, Sharpley Ann L. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database of Systematic Reviews. 2016(11). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009178.pub3/abstract.

142. Bighelli I, Trespidi C, Castellazzi M, et al. Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database of Systematic Reviews. 2016(9). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011567.pub2/abstract.

143. Gillies D, Sampson S, Beck A, Rathbone J. Benzodiazepines for psychosis‐induced aggression or agitation. Cochrane Database of Systematic Reviews. 2013(4).

144. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews. 2012(11).

145. Corrigan R, Derry S, Wiffen Philip J, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews. 2012(5). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009486.pub2/abstract.

146. Simon ST, Higginson IJ, Booth S, Harding R, Weingärtner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults. Cochrane Database of Systematic Reviews. 2016(10).

147. Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2012(1).

148. Zhong G, Wang Y, Zhang Y, Zhao Y. Association between Benzodiazepine Use and Dementia: A Meta‐Analysis. PLoS One. 2015;10(5):e0127836.

149. Mehdi T. Benzodiazepines Revisited. BJMP. 2012;5(1):a501. 150. Canadian Agency for Drugs and Technologies in Health (CADTH) Rapid Response Report:

Reference List. Long‐Term Use of Benzodiazepines: Clinical Effectiveness and Safety. 6 July 2015. https://www.cadth.ca/sites/default/files/pdf/htis/july‐2015/RA0782%20Long‐Term%20Benzodiazepine%20Safety%20Final.pdf.

151. Billioti de Gage S, Pariente A, Begaud B. Is there really a link between benzodiazepine use and the risk of dementia? Expert opinion on drug safety. May 2015;14(5):733‐747.

152. Sim F, Sweetman I, Kapur S, Patel MX. Re‐examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J Psychopharmacol. Feb 2015;29(2):212‐223.

153. Nardi AE, Freire RC, Mochcovitch MD, et al. A randomized, naturalistic, parallel‐group study for the long‐term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. Feb 2012;32(1):120‐126.

154. Stege G, Heijdra YF, van den Elshout FJ, et al. Temazepam 10mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med. Apr 2010;104(4):518‐524.

155. Oude Voshaar RC, Couvee JE, Balkom AJ, Mulder PG, Zitman FG. Strategies for discontinuing long‐term benzodiazepine use: meta‐analysis (Structured abstract). British Journal of Psychiatry. 2006(2):213‐220. http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE‐12006008419/frame.html.

156. Chung JK, Nakajima S, Shinagawa S, et al. Benzodiazepine Use Attenuates Cortical β‐Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F<sup>18</sup>‐Florbetapir Positron Emission Tomography. The American Journal of Geriatric Psychiatry.24(11):1028‐1039.

157. Lowry, F. Long‐term Benzodiazepine Use: No Risk for Cognitive Decline? June 01, 2016 http://www.medscape.com/viewarticle/864099. 158. Gray SL, Dublin S, Yu O, et al. Benzodiazepine use and risk of incident dementia or cognitive

decline: prospective population based study. BMJ (Clinical research ed ). 2016;352:i90. 159. Bobo WV, Reilly‐Harrington NA, Ketter TA, et al. Effect of adjunctive benzodiazepines on clinical

outcomes in lithium‐ or quetiapine‐treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial. J Affect Disord. Jun 2014;161:30‐35.

68

160. Bobo WV, Reilly‐Harrington NA, Ketter TA, et al. Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study. J Clin Psychopharmacol. Feb 2015;35(1):68‐74.

161. Klein E. The role of extended‐release benzodiazepines in the treatment of anxiety: a risk‐benefit evaluation with a focus on extended‐release alprazolam. J Clin Psychiatry. 2002;63 Suppl 14:27‐33.

162. Klein E. Discontinuation of benzodiazepines in patients with anxiety disorders: a focus on alprazolam and alprazolam extended release. Current therapeutic research, clinical and experimental. 1995(9):969‐974. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/339/CN‐00171339/frame.html.

163. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther. 1995(3):356‐365. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/409/CN‐00112409/frame.html.

164. Leufkens TR, Vermeeren A, Smink BE, Ruitenbeek P, Ramaekers JG. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology (Berl). 2007(4):951‐959. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/518/CN‐00586518/frame.html.

165. Buckley NA, Dawson AH, Whyte IM, O'Connell DL. Relative toxicity of benzodiazepines in overdose. Bmj. Jan 28 1995;310(6974):219‐221.

166. Isbister GK, O'Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. Jul 2004;58(1):88‐95.

167. Horsfall JT, Sprague JE. The Pharmacology and Toxicology of the 'Holy Trinity'. Basic Clin Pharmacol Toxicol. Feb 2017;120(2):115‐119.

168. Grushka M, Epstein J, Mott A. An open‐label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Nov 1998;86(5):557‐561.

169. Gremeau‐Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: a randomised placebo‐controlled study. Pain. Mar 2004;108(1‐2):51‐57.

170. Buchanan J, Zakrzewska J. Burning mouth syndrome. BMJ Clin Evid. Mar 14 2008;2008. 171. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment

of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. Apr 1990;147(4):445‐451.

172. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence‐based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. Jul 30 2013;81(5):463‐469.

173. Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. Apr 2011;20(4):173‐196.

174. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Medicine. May 2015;175(5):827‐834.

175. This Month’s Expert: John M. Talmadge, M.D., on Using Benzodiazepines in Substance Abusers. https://pro.psychcentral.com/this‐months‐expert‐john‐m‐talmadge‐m‐d‐on‐using‐benzodiazepines‐in‐substance‐abusers/002533.html. Accessed 7 July 2017.

176. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co‐occurring substance use disorders. Psychiatr Serv. Oct 2003;54(10):1395‐1401.

177. Landry MJ, Smith DE, McDuff DR, Baughman OL, 3rd. Benzodiazepine dependence and withdrawal: identification and medical management. J Am Board Fam Pract. Mar‐Apr 1992;5(2):167‐175.

178. Kryspin‐Exner K, Demel I. The use of tranquilizers in the treatment of mixed drug abuse. Int J Clin Pharmacol Biopharm. Jul 1975;12(1‐2):13‐18.

69

179. Rothstein E, Cobble JC, Sampson N. Chlordiazepoxide: long‐term use in alcoholism. Ann N Y Acad Sci. 1976;273:381‐384.

180. Sokolow JD, Welte J, Hynes G, Lyons J. Multiple substance abuse by alcoholics. Br J Addict. 1981;76:147‐158.

181. Romach M, Busto U, Somer G, Kaplan HL, Sellers E. Clinical aspects of chronic use of alprazolam and lorazepam. Am J Psychiatry. Aug 1995;152(8):1161‐1167.

182. Hirschfeld, RM, Bowden CL, Gitlin MJ, et al. Practice Guideline for the Treatment of Patients with Bipolar Disorder. 2nd ed. Arlington, VA: American Psychiatric Association; 2002. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf.

183. CANADIAN NETWORK for MOOD and ANXIETY TREATMENTS. http://www.canmat.org/canmatpub.html.

184. Grunze H, Vieta E, Goodwin, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania [published correction appears in World J Biol Psychiatry. 2009;10(3):255]. World J Biol Psychiatry. 2009;10(2):85‐116.[PubMed 19347775]. http://www.tandfonline.com/doi/pdf/10.1080/15622970902823202.

185. Katz MH. Opioid Prescribing for Chronic Pain: Not for the Faint of Heart. JAMA Internal Medicine. May 1 2016;176(5):599‐601.

186. TennCare Prior Authorization Form Benzodiazepine Agents (Revision History: 07/01/2016). https://tenncare.magellanhealth.com/static/docs/Prior_Authorization_Forms/TennCare_Benzodiazepines_PA_Request_Form.pdf.

187. Lexicomp (AHFS Essentials (Adult and Pediatric)). http://online.lexi.com/lco/action/doc/retrieve/docid/essential_ashp/410473.

188. Lexi‐Comp I, ed Drug Information Handbook. 21st ed. Hudson, OH: Lexi‐Comp; 2016. 189. McEvoy GK, Snow EK, Kester L, Litvak K, Miller J, Welsh OH, eds. AHFS 2016 Drug Information.

Bethesda, MD: American Society of Health‐System Pharmacists; 2016.

UTAH MEDICAID DUR REPORT JUNE 2017 BENZODIAZEPINES · 2019. 10. 30. · prescriptions were issued...

Documents

Transcript of UTAH MEDICAID DUR REPORT JUNE 2017 BENZODIAZEPINES · 2019. 10. 30. · prescriptions were issued...